



Review

Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity

Anna Lucia Fedullo ¹, Antonio Schiattarella ², Maddalena Morlando ², Anna Raguzzini ¹, Elisabetta Toti ¹, Pasquale De Franciscis ² and Iliaria Peluso ^{1,*}

¹ Research Centre for Food and Nutrition, Council for Agricultural Research and Economics (CREA-AN), 00178 Rome, Italy; annalucia.fedullo@libero.it (A.L.F.); anna.raguzzini@crea.gov.it (A.R.); elisabetta.toti@crea.gov.it (E.T.)

² Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, 80138 Naples, Italy; aschiattarella@gmail.com (A.S.); madmorlando@gmail.com (M.M.); pasquale.defranciscis@unicampania.it (P.D.F.)

* Correspondence: ilaria.peluso@crea.gov.it

Abstract: The aim of this review is to highlight the influence of the Mediterranean Diet (MedDiet) on Gestational Diabetes Mellitus (GDM) and Gestational Weight Gain (GWG) during the COVID-19 pandemic era and the specific role of interleukin (IL)-6 in diabesity. It is known that diabetes, high body mass index, high glycated hemoglobin and raised serum IL-6 levels are predictive of poor outcomes in coronavirus disease 2019 (COVID-19). The immunopathological mechanisms of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection include rising levels of several cytokines and in particular IL-6. The latter is associated with hyperglycemia and insulin resistance and could be useful for predicting the development of GDM. Rich in omega-3 polyunsaturated fatty acids, vitamins, and minerals, MedDiet improves the immune system and could modulate IL-6, C reactive protein and Nuclear Factor (NF)- κ B. Moreover, polyphenols could modulate microbiota composition, inhibit the NF- κ B pathway, lower IL-6, and upregulate antioxidant enzymes. Finally, adhering to the MedDiet prior to and during pregnancy could have a protective effect, reducing GWG and the risk of GDM, as well as improving the immune response to viral infections such as COVID-19.

Keywords: cardio-diabesity; inflammation; oxidative stress; nutraceuticals; plant foods



Citation: Fedullo, A.L.; Schiattarella, A.; Morlando, M.; Raguzzini, A.; Toti, E.; De Franciscis, P.; Peluso, I. Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity. *Int. J. Mol. Sci.* **2021**, *22*, 1213. <https://doi.org/10.3390/ijms22031213>

Academic Editor: Pedro Gomes

Received: 29 November 2020

Accepted: 22 January 2021

Published: 26 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The ongoing coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide [1]. In order to reduce the spread of the infection, the management of the pandemic requires several measures across all continents, such as local lockdowns. These lockdowns have potential long-term side effects on risk factors for cardiovascular diseases (CVD), such as unhealthy diet and physical inactivity [2]. Increased intakes of energy-dense processed foods (such as high fat meals and sweets) and/or reduced energy expenditure has been proven to lead to diabesity [3]. The latter, indicating the coexistence of type 2 diabetes (T2D) and obesity [4], can be associated with other CVD risk factors (such as dyslipidemia and hypertension) in the metabolic syndrome (MetSyn) [5]. T2D, obesity, MetSyn, and CVD are collectively known as cardiometabolic [6,7].

There is a high prevalence of pre-existing comorbidities in patients with severe COVID-19 [8,9], with old age, smoking, hypertension, diabetes, and chronic obstructive pulmonary disease considered as risk factors for poor prognosis [10,11]. Individuals with diabetes—in particular those with higher body mass index (BMI) and with higher glycated hemoglobin (HbA1c)—are at higher risk of severe COVID-19 [11] (Figure 1). Patients with diabetes present an impairment in both innate and adaptive immunity that enhances their susceptibility to infections [12]. Moreover, the inflammatory response to

viral infections is also boosted with a higher risk of cytokine storm [13,14]. Both malnutrition and over-nutrition are associated with impaired immune function and/or chronic low-grade inflammation [15,16].




Figure 1. COVID-19, diabetes, and MedDiet interactions. ACE: Angiotensin-Converting Enzyme; COVID-19: Coronavirus Disease 2019, CVD: cardiovascular disease; GDM: Gestational Diabetes Mellitus; KEAP1: Kelch-Like ECH-Associated Protein 1; I-κB: Kappa b inhibitor; IL: interleukin; Nrf2: Nuclear Factor Erythroid-Derived 2-Like; SCFA: Short-Chain Fatty Acids.

Currently, the primary prevention of COVID-19 infection is based on the use of vaccines [17]. Monoclonal antibodies from Eli Lilly and Regeneron have been approved by the Food and Drug Administration (FDA) for treating COVID-19 patients [18], who also issued an emergency use authorization (EUA) for other drugs [19]. The available data suggest that the respiratory failure from acute respiratory distress syndrome (ARDS) is the leading cause of mortality. In a meta-analysis of 86 studies, severe COVID-19 was strongly associated with lymphocytopenia [20], hyperglycemia [21], ARDS [21], and high levels of interleukin (IL)-6 [20,21] and C-reactive protein (CRP) [20].

Despite the limited available data on COVID-19 in pregnant women, maternal mortality appears to be similar to non-pregnant women, while data on neonatal outcomes suggest an increased risk of complications [22–24]. Pregnancy can be associated with an impairment in glucose tolerance that could lead to the development of Gestational Diabetes Mellitus (GDM).

Non-pharmacological interventions in the management of diabetes include changes of lifestyle and dietary advice [25]. The effects of the ketogenic diet and of intermittent fasting on immunity and inflammation are controversial [16,26–29] due to the risk of ketoacidosis [29], which should be considered in women with GDM [30]. However, it is well known that the Mediterranean diet (MedDiet), rich in vegetables, legumes, nuts, cereals, and fish, is effective in preventing cardiometabolic disease [6,7].

MedDiet has been suggested for health promotion in the COVID-19 era [31,32]. Furthermore, it has been proposed that a balanced diet might improve the immune response to SARS-CoV-2 infection [15,16]. Moreover, the adoption of a healthy lifestyle (including diet and physical exercise) can reduce the risk factors associated with the thrombotic complications of COVID-19 [33]. Obesity is related to the hyper-coagulopathy observed in severe COVID-19 [34], and pregnant women with COVID-19 showed increased D-dimer and fibrinogen levels [35]. However, it has been suggested that the fibrinolysis system of pregnancy may protect pregnant women with COVID-19 from the development of severe illness [35].

On the other hand, obesity, diabetes mellitus, and raised serum IL-6 levels were predictive of poor pregnancy outcomes in the course of COVID-19 infection [36]. Furthermore, increased levels of IL-6 were shown in the newborns of infected mothers [37,38]. IL-6 has a role in the development of insulin resistance and hyperglycemia [39–42]. Pregnant women affected by GDM have also shown elevated IL-6 concentrations, compared to controls [43,44]. Liu et al. analyzed 51 newborns from mothers with COVID-19 during the third trimester and found that an infant who developed necrotizing enterocolitis presented higher IL-6 levels, compared to the other children [38].

This review aims to discuss the potential of MedDiet and its components on GDM and Gestational Weight Gain (GWG), with particular reference to the adipokine IL-6.

2. Lockdown, Lifestyle and Diabesity: Implications for Pregnancy

Mediterranean lifestyle habits include diet, physical activity, and social interaction [45], and some Mediterranean pyramids include emotional balance [46,47] or psychological wellness [48], all factors that can be influenced by lockdown. A recent review revealed more frequent snack consumption and a rise in the intake of carbohydrates with a high glycemic index during the COVID-19 pandemic [49]. Stress and depression during quarantine have also led to unhealthy diets and reduced physical activity in some individuals [50]. The metabolic consequences of confinement include increases in insulin resistance, total body fat, abdominal fat, and inflammatory cytokines [10]. All of these factors have been strongly associated with the development of MetSyn, which in turn increases the risk of chronic diseases [10].

During the COVID-19 pandemic, the lockdown period has led some obese individuals to increases in body weight, mainly caused by decreased exercise, solitude, anxiety/depression, and increased consumption of snacks, unhealthy foods, and sweets [51].

Patients with T2D reported a high consumption of sugary food and snacks [52–54], as well as increased stress and reduced exercise [54]. Furthermore, associations were found between food cravings and snack consumption [52], increased snack consumption and/or decreased exercise levels and body weight gain [54], increased total diet intake and raised HbA1c concentrations [54]. A poor glycemic control was found in T2D patients with an unhealthy diet and low physical activity [55]. T2D patients with mental stress also had unhealthy dietary habits [55].

During pregnancy, the psychological state is an important factor to consider because a high “Negative Affect Score” was found to reduce the favorable effects of a high “Mediterranean Diet Score” on the “Homeostasis Model Assessment of Insulin Resistance” (HOMA-IR) [56].

During lockdown, psychological stress was among the most common factor that worsened hyperglycemia, followed by changes in diet and exercise [57]. Furthermore, some patients required additional medications to control blood glucose levels during lockdown [57]. In women with GDM, the use of insulin therapy was significantly higher in 2020 (47.7%) compared with 2019 (36.2%) [58]. These results were explained by anxiety, dietary habits, and reduced physical activity [58]. In France, a higher rate of poor postprandial glycemic control was observed during the COVID-19 lockdown from 18 March 2020 to 7 May 2020 (13.7%), as compared with the same period during 2019 (8.7%) [58]. In Italy, it has been reported that diet therapy and/or insulin were sufficient to obtain a favorable maternal and fetal outcome in women with GDM and a concomitant SARS-Cov-2 infection [59]. In China, during the COVID-19 pandemic, a higher emotional eating score was associated with a significant excess of GWG [60]. After adjustments for exercise, the emotional eating score was also associated with a decreased consumption of fish and seafood [60].

In the “Croatian Islands Birth Cohort Study” adherence to the MedDiet ranged from low to moderate among pregnant women, with the highest adherence seen among women with healthier lifestyles [61]. Moreover, low adherence to a MedDiet pattern in healthy Spanish women before pregnancy was related to smoking habits and sedentary lifestyles [62]. However, a survey conducted in May 2020 reported that pregnant Spanish

women decreased their physical activity and increased their sitting time after the confinement, whereas no differences were found in eating patterns [63]. Results from the “Australian Longitudinal Study on Women’s Health” reported that the MedDiet was inversely associated with the risk of developing gestational hypertension and pre-eclampsia [64]. Moreover, several follow-up studies in women with a history of GDM from the Nurses’ Health Study II cohort suggested that, in order to lower subsequent risk of developing hypertension [65] and T2D [66], it could be helpful to adhere to a healthy dietary pattern. The inverse association between T2D and healthy diets is partly mediated by BMI [66], and healthy diets are associated with lower weight gain regardless of other lifestyle factors [67].

3. Diabesity, Meta-Inflammation, and IL-6: The Role in Severe COVID-19

SARS-CoV-2 infiltrates human cells and binds to the angiotensin-converting enzyme 2 (ACE2) receptor, which is more expressed in individuals with diabetes and/or those in treatment with ACE inhibitors and angiotensin receptor blockers [68] (Figure 1). Dysregulation of the ACE2 pathway in the pancreas causes β -cell dysfunction and induces hyperglycemia [69]. The latter [28] and hyperinsulinemia [70] play a crucial role in thromboinflammation during COVID-19 infection. Countries with higher and lower death rates for COVID-19 appear to have high consumptions of fats and cereal, respectively [71]. Hyperglycemia and Reactive Oxygen Species (ROS)-induced oxidation of carbohydrates generate the adduct derivatives advanced glycation end products (AGE) [72]. The activation of the receptor for the advanced glycation end products (RAGE), which is also expressed in the lungs, produces a pro-inflammatory response via nuclear factor (NF)- κ B, by increasing the NF- κ Bp65 expression and the degradation of I κ B [73]. Accumulation of AGE could prime an exaggerated cytokine response to viral infection and ARDS [74]. It has also been suggested that SARS-CoV-2 could activate RAGE, a pattern recognition receptor that recognizes both pathogen-associated molecular patterns from microorganisms and danger-associated molecular patterns released by damaged cells [73,74]. Infection with SARS-CoV-2 also perturbs the renin–angiotensin system, favoring angiotensin II receptor 1 activation and potentially transactivating RAGE [74]. In overweight/obese individuals (BMI \geq 27 kg/m²) the reduced ACE2 mRNA expression in subcutaneous adipose tissue was associated with an improvement of insulin sensitivity of skeletal muscle during weight reduction over 3 months [75]. Moreover, the small intestine expression of ACE2 receptors and respiratory virus infection is associated with dysbiosis of the gut microbiota [76] (Figure 1). Dysbiosis and endotoxemia have been implied in the observed increase of COVID-19 severity in obesity [77]. Metabolic endotoxemia could be induced by the direct diffusion of the Gram negative endotoxin lipopolysaccharide (LPS) from the intestinal lumen, due to intestinal paracellular permeability resulting from dysbiosis [78,79], or through the absorption by enterocytes during the secretion of chylomicrons in the postprandial state [80]. LPS activates “oxidative burst” in neutrophils and macrophages [81], leading to the formation of oxidized low-density lipoproteins and atherosclerotic plaques [82]. The overexpression and the activation (by LPS) of toll-like receptor (TLR)4 [78,82], as well as the ROS-mediated activation of p38 mitogen-activated protein kinase (MAPK) signaling and NF- κ B [78,83], are involved in meta-inflammation. The latter [78] has been identified among mechanisms that link obesity, T2D, non-communicable diseases [79,83,84], and poor host response to viruses [14]. Meta-inflammation and chronic low-grade inflammation are observed in obese individuals, and characterized by high levels of circulating pro-inflammatory cytokines including IL-6 [78,79,85].

The mechanisms of SARS-CoV-2 infection include cytokine storm syndrome, an auto-amplifying cytokine production that occurs due to an unregulated host immune response, and involves IL-6. The IL-6 receptor antagonist tocilizumab has been used in some cases of severe COVID-19 [86–90]. However, the benefits of tocilizumab for the treatment of COVID-19 are uncertain, [91–100] and the Italian Medicines Agency (AIFA) announced on June 18, 2020 that tocilizumab (Actemra) did not improve COVID-19 outcomes [91–93]. However, a recent meta-analysis reported a reduced mortality prevalence in patients treated with

tocilizumab [97]. Sarilumab is another IL-6 receptor antagonist under investigation in clinical trials [91,98,99]. In addition to IL-6 receptor targeting, clinical trials with anti-IL-6 treatments (clazakizumab and siltuximabin) are ongoing [99]. However, more studies are needed in order to assess the safety and efficacy of IL-6 signal inhibitors [100].

Only two case reports demonstrated successful tocilizumab therapy in pregnant women with TD2 [101] or GDM [102], however one of these observed transaminitis and hyper-triglyceridemia after treatment [102]. Although pregnancy is not a significant risk factor for severe COVID-19, obesity in pregnant women represents a key co-morbidity and high circulating levels of leptin have been associated with an increased mortality in patients with ARDS [103]. Moreover, the increased levels of leptin are pro-inflammatory [93] and could induce macrosomia in the fetus [104].

The expansion of adipose tissue promotes macrophage infiltration and the production of leptin and other inflammatory adipokines, including Tumor Necrosis Factor alpha (TNF)- α and IL-6 [85]. IL-6 and CRP are associated with hyperglycemia and insulin resistance [78]. IL-6 has also been suggested as a marker able to predict T2D development [78]. IL-6 is a critical signaling molecule released from fat cells and belongs to obesity-related cytokines [105,106].

The causes of GDM remain uncertain, but recent literature has hypothesized the pivotal role of the immune system in inception and development of this disease. Other components have been involved in the pathogenesis of GDM such as oxidative stress and obesity. Several studies also underlined that an imbalance between T helper (Th)1 and Th2 cells has a critical role in cytokine production in women affected by GDM [107]. During normal pregnancy, T helper cells showed a pro-inflammatory Th1 profile, by mediating the production of interleukin IL-2, interferon (IFN)- γ , and TNF- α . Higher levels of these molecules have been found in patients affected by GDM compared to controls [108]. On the other hand, the Th2 profile is characterized by an anti-inflammatory response through the production of several interleukins such as IL-10, IL-4, IL-5, and IL-13. [109]. Elevated concentrations of IL-6 and CRP might predict the onset of GDM [110].

It is well known that fat distribution has a role in obesity-induced T2D [111]. Peripheral obesity is associated with “alternatively activated” M2 macrophages, Th2, and regulatory T cells [111]. The latter produce IL-10, which could inhibit the ability of TNF- α to downregulate the Glucose Transporter (GLUT)-4 expression and to impair the insulin action in adipocytes [112]. However, individuals with central obesity are characterized by infiltration of proinflammatory Th1, Th17, and “classically activated” M1 macrophages [111] (Figure 1). In adipose-tissue biopsies of overweight/obese individuals, proinflammatory Th1 and Th17 were more frequent in visceral adipose tissue (VAT) than in subcutaneous adipose tissue (SAT) [113]. Recent studies found that pregnant women had higher total lymphocyte counts in VAT compared to SAT regardless of GDM [114] and that higher VAT better predicts GDM than pre-pregnancy BMI [115]. Infiltration of proinflammatory Th cells into VAT is recognized as one of the primary events in obesity-induced chronic inflammation, and diet-induced obesity promotes the expression of T-cell co-stimulatory molecules on the surface of adipose tissue macrophages and of VAT resident dendritic cells [112]. Dendritic cells are the major contributors to the induction of T17 cells in adipose tissue possibly via expressing high levels of IL-6, transforming growth factor- β , and IL-23 [112]. The role of IL-6 is controversial because it is an inflammatory cytokine involved in Th17 differentiation and its plasma concentration correlated with Th1 in SAT from adipose-tissue biopsies of overweight/obese individuals [113], but IL-6 release from exercising muscle has been suggested to inhibit the LPS-induced TNF- α production [116], limiting inflammation during endotoxemia [117]. Moreover, IL-6 induced expression of the receptor for IL-4 and increased the response to IL-4 in macrophages and their alternative activation [117,118]. Obesity is accompanied by a switch in macrophage activation from the M2 macrophages to the proinflammatory M1 macrophages [112], and the hyperactivation of M1 macrophages is linked to aerobic glycolysis and hyperglycemia [28]. Data from animal models suggest that pregnancy is associated with an alternatively activated phenotype of alveolar macrophages

before infection, which may contribute to the increased inflammatory response to influenza virus infection and to heightened disease severity [119]. Furthermore, the polarization of macrophages has a role in pre-eclampsia, recurrent spontaneous abortion, infertility, intrauterine growth restriction, and preterm labor [120]. In a case-control study, peripheral blood monocytes showed that pro-inflammatory M1-like phenotype and M1 macrophage infiltration was increased in the placenta of women with pre-eclampsia compared with controls, and pro-inflammatory factors—including IL-6—were significantly increased in the serum and placenta of women with pre-eclampsia [121]. Data from animal models suggested that the adipose tissue M1 or M2 phenotypes under postnatal high fat diet in offspring was affected by maternal undernutrition due to protein restriction [122]. Moreover, within adipose tissue macrophages there was an increase of IL-6 gene expression [122].

The impact of different dietary approaches on metabolism, inflammation, and long-term outcomes has been extensively studied. In a systematic review and meta-analysis of 74 trials evaluating the effects of high- versus low-protein diets, a higher reduction of BMI, waist circumference, and fasting insulin were observed with the high-protein diet, however the effects on fasting glucose and HbA1c were not significant between the two diets and adverse gastrointestinal events were also reported with the high-protein diet [123]. In this context, it is known that diet rapidly alters microbial community [124] and a position paper suggested caution regarding the use of high-protein diets in the long-term, due to the effect on microbiota and gene expression in the gut [125]. Despite the potential advantages for the metabolism of anti-inflammatory M2 macrophages by the reduction of glucose availability for activated M1 macrophages through an eucaloric ketogenic diet [28], Tagliabue et al. reported that prolonging the ketogenic diet for 3 months increased *Desulfovibrio* spp., which is involved in the exacerbation of the inflammatory condition of the gut mucosa associated with the consumption of fats of animal origin [126]. Furthermore, in diabetic patients, restriction of carbohydrates to below 26% of total energy, compared to a diet with carbohydrates at more than 45% total energy produced greater reductions in HbA1c at 3 and 6 months, but no significant difference at 12 or 24 months were found [127]. A consensus statement from the Italian Society of Endocrinology [128] concluded that concern still exists about potential risks of very-low-calorie ketogenic diets in the long-term.

MedDiet—as well as low-carbohydrate, low-glycemic index, and high-protein diets—decreased HbA1c compared with their control diets, but the greater effect was observed with the MedDiet as it also reduced body mass significantly [129]. Data from meta-analysis in individuals with T2D and/or prediabetes reported that MedDiet reduced fasting glucose and body mass compared to other diets, including the diet suggested by the American Diabetes Association and the European Association for the Study of Diabetes (50–55% carbohydrates with mixed glycemic index, 30% fat and 15–20% protein) [130].

4. Mediterranean Diet for Prevention of Obesity and Gestational Diabetes

The Western diet, characterized by a high consumption of sugar and saturated fats contributes to the predominance of obesity and T2D, activates the innate immune system, and impairs adaptive immunity. These lead to chronic inflammation and an impaired host defense against viruses, which could place people in this category at an increased risk for severe COVID-19 [131].

The role of an elevated BMI in the spreading of GDM has been widely analyzed by previous studies [132,133] and it is known that it highly impacts the immune system and the related increase of circulating inflammatory cytokines during pregnancy [134]. However, it has been speculated that cytokine production could be enhanced by other sites besides adipose tissue such as immune cells in placenta [135].

An observational study on pregnancy of women comparing the western dietary pattern, a traditional dietary pattern, and a healthy dietary pattern (high in green, leafy and colored vegetables) demonstrated a borderline significant inverse association between high adherence to a healthy dietary pattern and the chance of pre-eclampsia [136]. Both Dietary

Approaches to Stop Hypertension (DASH—including fruits, veggies, whole grains, and low-fat dairy) and MedDiet were related to lower fasting blood glucose, HbA1c, and serum triacylglycerol levels. High-density lipoprotein cholesterol was higher for those following DASH while total serum cholesterol was lower for those in the MedDiet. Participants that had high adherence to the MedDiet had 80% lower risk for GDM, while greater adherence to the DASH pattern was associated with 71% reduced risk for GDM [137]. Lower risks or odds of GDM were associated with higher physical activity levels before or in early pregnancy and to MedDiet/DASH [138]. These results strengthen the importance of dietary advices in pre-gravid women [139]. As usual, the target weight will differ according to the physiological and/or pathological state of women, and consequently the energy intake should be personalized [140].

Several studies described an inverse association among GWG [141] and GDM [142] related to MedDiet, whereas adequacy of vitamins (B9, D, and E) and dietary fibre were related to the adherence to MedDiet during pregnancy [143]. GWG seems to be related to the intakes of added sugar, but not to saturated fat or protein. In order to limit GWG, it was found to be relevant to reduce foods that contain added sugar such as snacks, sweets, and soft drinks [144]. However, an elevated risk of deflection from recommended GWG was observed in women with low MedDiet adherence [145]. A high baseline adherence to the MedDiet was linked to a lower weight gain during pregnancy and thus may protect against obesity and becoming overweight [146]. Following a MedDiet pre-pregnancy seems to be effective in preventing GDM and other maternofetal outcomes [147]. Compliance with MedDiet before the 12th gestational week was associated with a reduction of GDM [148] and with health benefits for the offspring, particularly in women with a pre-gestational BMI lower than 25 kg/m² and normal glucose tolerance [149]. It was proven that also a late first-trimester (>12 gestational weeks) degree of adherence to a MedDiet pattern seems to positively impact on a composite materno-fetal outcome (CMFCs) such as perineal trauma, emergency C-section, pre-eclampsia, pregnancy-induced hypertension, prematurity, and large or small-for-gestational-age (SGA). The risk of GDM, CMFCs, prematurity, and SGA newborns decreased linearly with high, moderate, and low adherence to MedDiet [150–152].

A critical role in the progression of GDM could be proven by the inflammasome activation. This is mediated by caspase-1 and increases IL-1 β concentration, a pro-inflammatory cytokine that impacts on insulin resistance. Higher levels of these molecules have been found in women affected by GDM [153]. Moreover, women with GDM had higher HbA1c levels at 24–28 gestational weeks compared to controls while the values were similar at 36–38 gestational weeks. Similarly, fasting serum insulin and HOMA-IR were higher in women with GDM at 24–28 gestational weeks but became similar at 36–38 gestational weeks [154]. Adherence to a MedDiet nutritional approach is related to a lower incidence of GDM and a better glucose tolerance (even in women without GDM) [152] and to a decreased risk of MetSyn [155]. The “Seguimiento Universidad de Navarra” project assessed the association of total, processed, and unprocessed red meat and iron intake with the risk of developing GDM in pregnant women [156]. It was found that a higher risk of GDM was significantly associated with total meat consumption, especially for red meat and processed meat. Non-heme and total iron intake, including supplements, are not associated with GDM. On the contrary, heme-iron intake was directly associated with GDM, but the statistical significance was lost when adjusted for red meat consumption [156]. Furthermore, a consumption of more than two sugar-sweetened soft drinks per week was an independent risk factor for GDM [157].

Transmission of obesity across generations is a reason of concern. High offspring adiposity at birth and overweight status in childhood may be associated with pre-pregnancy overweight/obesity and with an excessive GWG, respectively [158]. High birth weight, which is linked to subsequent MetSyn, seems to be linked with a high intake of carbohydrate during pregnancy combined with impaired glucose tolerance [159]. There is strong evidence that epigenetic changes during fetal development play a fundamental role in

the development of MetSyn. These changes are induced by maternal nutrition, among different factors, affecting the intrauterine environment. Likewise, the MedDiet could have a similar action during pregnancy, protecting the fetus against the development of MetSyn throughout life [160]. In obese women, even those without GDM but with impaired glucose tolerance, a lower carbohydrate intake at moderate levels in late gestation is associated with a lower fat mass in their offspring at birth [160].

Growing evidence advises on the beneficial effect of the MedDiet for women of reproductive age and during pregnancy on children's health against prematurity, fetal growth, neural tube defects and other congenital pathologies, as well as against asthma and allergies, body weight, and metabolic markers [161,162]. In fact, children born from mothers that followed a MedDiet during pregnancy are protected against cardiometabolic risk such as blood pressure, and blood levels of lipids, CRP, and adipokines [163]. Therefore, MedDiet lifestyles should be incorporated into strategies for prevention and treatment of overweight/obesity especially in women of childbearing age [158]. Compared to controls, women with GDM had higher rates of insufficient weight gain, SGA, and neonatal intensive care unit admission, while the rates of macrosomia, large for gestational age, pregnancy-induced hypertensive disorders, prematurity and cesarean sections were similar [154]. In addition, maternal regimen during pregnancy might also influence the development of childhood allergic disorders. An increased risk of wheeze in the first year of life was associated with high meat intake and processed meat intake during pregnancy, while a high intake of dairy foods was significantly associated with a decreased risk [164]. Finally, high adherence to the MedDiet during pregnancy seems to be associated with a reduced incidence of allergic sensitization, allergic rhinitis, and wheeze in the first year of life [165,166].

5. Mechanisms of the Mediterranean Diet Components

It is well known that omega-3 polyunsaturated fatty acids (omega-3 PUFA), vitamins (folate, A, B6, B12, C, D, and E) and minerals (copper, iron, magnesium, selenium, and zinc), improve the immune system [167–173]. Although supplementations with omega-3 PUFA and/or micronutrients have been suggested to improve clinical outcomes of patients with ARDS [174–177] and to improve public health [167,177], it has been pointed out that only individuals at high-risk of specific nutrient deficiencies could benefit from supplementation, whereas the supplementation of a single nutrient is not promising in the general population [178]. Moreover, it has been recently found that zinc supplementation in pregnant women decreased hemoglobin concentration [179]. On the other hand, it has been suggested that vitamin D could modulate IL-6 concentrations [180], whereas an appropriate magnesium status activates the functionality of vitamin D and reduces IL-6, CRP, and NF- κ B [181]. In pregnant women, supplementation with vitamin D did not improve their IL-6 serum but it was higher in the 1000 IU/d (25.9 ± 32.0 ng/L) than in 2000-IU/d group (4.6 ± 1.4 ng/L) [182].

Vitamin D has been identified as a potential candidate in the prevention of GDM [183]. Data from a recent meta-analysis reported that the combination of exercise and diet or supplementation with vitamin D reduced GDM risk [184]. In consideration of the lockdown measures, the reduced exposure to sunlight and therefore the consequent reduction of endogenous vitamin D production, could represent a critical point on the development of this pathology. The supplementation with docosahexaenoic acid (DHA) and multiple micronutrients during the second and third trimesters of pregnancy improved women's DHA and vitamin D status compared to controls, without affecting significantly the glutathione status and 8-isoprostane [185]. Moreover, in a recent meta-analysis omega-3 PUFA did not reduce the risk of GDM, whereas more studies are needed to establish the effect of vitamins, minerals, or probiotics [184].

MedDiet can be considered a natural supplement that includes fibre, omega-3 PUFA, and polyphenols, with the gut microbiota appearing to be the main target and player in the interactions occurring between omega-3 PUFA, polyphenols, probiotics, and prebiotics [186,187].

Some phenolic compounds are able to induce insulin secretion (apigenin, cyaniding, delphinidin, catechins, and quercetin) [81] and increase the GLUT4 insulin-mediated glucose uptake in adipocytes or skeletal muscle cells (catechins, procyanidins, and phenols of extra virgin olive oil (EVOO)) [188,189]. Furthermore, plant-foods' bioactive compounds inhibit the GLUT2 and the sodium-dependent glucose transporter (catechins and quercetin), as well as the activity of α -glucosidase (anthocyanins, catechins, flavanones, flavones, flavanols, and isoflavones) or α -amylase (quercetin, luteolin, and myricetin) [81,188,189]. These mechanisms are among the major strategies for reducing the risk of diabetes including slowing (increase fibre consumption) or reducing (amylase and glucosidase inhibition) carbohydrate absorption [190]. However, diarrhea and flatulence are the most frequent side-effects to acarbose, due to its inhibition of starch digestion [191] and fibre can lead to similar gastrointestinal problems [190]. It has been suggested that when the COVID-19 infection involves the intestine of obese individuals, dysbiosis could contribute to the cytokine storm [192]. Dietary fats induce dysbiosis and may increase intestinal permeability, inducing endotoxemia and chronic low-grade inflammation [192], whereas polyphenols modulate microbiota composition [186]. Although antiviral properties against SARS-CoV-2 (related to virus entry into the cells) have been reported in vitro for some bioactive phytochemicals (Figure 1), including the hesperidin [193,194], quercetin [194,195], kaempferol [194], catechins [194,196], baicalin [197], curcumin [194] and resveratrol [194], their availability in humans is low [198]. Only 5–10% of dietary polyphenols can be absorbed and they undergo to microbial metabolism in the colon [188]. However, it has been proposed that the products of microbial fermentation of dietary polyphenols could be responsible for antioxidant and anti-inflammatory activities and that polyphenols enrich the gut with beneficial bacteria [188] (Figure 1). In this context, it has been recently suggested that tailored nutrition and supplementation, known to improve the intestinal microbiota and its immune function, might help to minimize the impact of the disease at least on people at higher risk from COVID-19 [199–202]. Probiotics, prebiotics, dietary fibre, and their symbiotic combinations improve health through the production of short-chain fatty acids (SCFA) that modulate immune functions [76,202,203], inhibiting the NF- κ B pathway and lowering IL-6 [204,205] (Figure 1). Moreover, it has been suggested that β -glucan from the baker's yeast *Saccharomyces cerevisiae*, with a diet rich in vitamins C and D, can improve microbiota and immune response to respiratory virus infections, and reduce inflammation and coagulation abnormalities [206]. Furthermore, low-purine diets and *Lactobacillus gasseri* reduce intestinal purine absorption and have been suggested for improving the immune system and weakening viral replication in individuals with hyperuricemia [207]. Although uric acid is the major antioxidant in biological fluids [72,208], at concentrations above the saturation level it can be a dangerous signal for the immune system [82]. In order to decrease uric acid it is important to reduce the consumption of sardines, liver and kidneys [207], as well as fruit juices (containing fructose) [209] and alcoholic beverages [207,210]. Although the green tea epigallocatechin gallate can reduce uric acid [211,212], it can also activate the nuclear factor erythroid-derived-2-like-2 (Nrf2)/ antioxidant responsive element (ARE) signaling by pro-oxidant mechanisms [213]. Moreover, it has been pointed out that high consumption of green tea is associated with low serum folate levels during pregnancy and an increased risk of neural tube defects [198] and case reports of severe anemia after consumption of large amounts of tea have been described [214,215]. In agreement, *Camellia sinensis* products are among the herbal extracts used to enhance immune system function for which the safety should be determined in pregnancy [216]. It has recently been pointed out that pregnant women are under-represented in clinical studies, and there is a need for more evidence with respect to drug and nutraceuticals safety and pharmacokinetics [217]. Although, in animal models, some bioactive phytochemicals—including resveratrol—had positive effects on embryo/fetal development and maternal health, however others—such as epicatechin gallate and curcumin—had adverse effects [198] and caution in the consumption of soy food and phytoestrogens during pregnancy has been suggested [198].

The mechanism suggested for Nrf2 and/or NF- κ B modulation by polyphenols is the interaction of electrophiles with cysteine residues of Kelch-like ECH-associated protein 1 (KEAP1), I- κ B, and/or I-kappa kinases [218] (Figure 1). Preclinical evidence indicates that lactic acid bacteria can modulate both Nrf2 and NF- κ B pathways, and that sulforaphane, produced by the gut microbiota from the glucoraphanin contained in cruciferous (Brassica) vegetables, activates Nrf2 [219]. Moreover, it has been proposed that fermented cabbage may induce the Nrf2-mediated antioxidant response, and consequently reduced IL-6 [219]. The ROS-mediated activation of Nrf2, with resulting upregulation of antioxidant enzymes is a common mechanism of plant food polyphenols [78,189]. Polyphenol-rich foods and beverages include fruit, vegetables, cereals, EVOO, nuts, herbs, spices, coffee, chocolate, tea, and red wine [198,220]. Therefore, Nrf2 is among the factors involved in the hormesis proposed to explain the anti-inflammatory and antioxidant effects of the MedDiet [78,189,221]. In particular, some dietary phytochemicals—including phenolic antioxidants, glucosinolates, and resveratrol—act in a hormetic-like manner through the modulation of stress-response pathways and are called hormetins [221]. Nrf2 activity in response to ROS and xenobiotics is regulated by the thiol-rich protein KEAP1 [72,219] (Figure 1). The induction of the ARE and of the ROS-mediated pathway by Nrf2 reduces the activity of NF- κ B [219]. NF- κ B is localized in the cytoplasm associated with the I- κ B inhibitor (Figure 1), and under the effect of inflammatory cytokines, including IL-6, I- κ B is degraded and NF- κ B translocates into the nucleus and induces the expression of cytokines, inducible nitric oxide synthase and cyclooxygenase 2 [222]. Inflammatory cytokines and ROS activate the MAPK [222], involved in the concerted modulation of redox regulated Nrf2 and NF- κ B gene expression in inflammation and carcinogenesis [223]. Studies in vitro or in animal models reported that resveratrol, naringin and hesperidin reduced IL-6 and/or the activation of NF- κ B and p38 MAPK pathway [220]. IL-6 and p38-MAPK are also involved in the over-expression of p-glycoprotein, inducing chemoresistance [223]. In this context, it has been suggested that MAPK could be a target of EVOO compounds, including squalene acting as “natural delivery system” of bioactive phytochemicals [223]. Moreover, EVOO has a role in the anti-inflammatory effects of the MedDiet [224], also reducing IL-6 [225]. Both polyphenols and omega-3 PUFA inhibit NF- κ B, MAPK, and/or TLR4 pathways [220,222]. However, in a meta-analysis of intervention studies, no significant difference was detected between flavonoid ingestion and control for the differences in plasma IL-6 concentration [226]. Omega-3 PUFA reduced IL-6 in preclinical studies and in elderly and obese individuals [222] but did not affect IL-6 levels in healthy individuals [222]. Omega-3 PUFA have been suggested for ameliorating the lung damage that occurs during COVID-19 [227]. However, omega-3 PUFA could make membranes more susceptible to ROS [228] and it has been suggested that vitamin E protects them and the immune cells from oxidation [205]. Therefore, MedDiet rather than single supplementation could be useful for health. Accordingly, data from a meta-analysis reported that while dietary patterns rich in polyphenols reduced the risk of GDM despite polyphenol-rich food groups—including polyphenol-rich fruit (berry, apple, and other pome fruit) and non-alcoholic beverage consumption (tea, cocoa, coffee, orange, and apple juices)—whole grains and legumes did not [229]. Furthermore, the consumption of potatoes or drupe (cherry, nectarine and plum) could increase the risk of GDM [229]. On the contrary all the included studies on MedDiet reported a significantly lower risk of GDM among women with the highest score of adherence [229].

6. Conclusions

The COVID-19 pandemic generates a great interest in dietary advice, supplements, nutraceuticals, and complementary/alternative medicine (CAM) in order to improve immune function [170,230–232]. However, there is no evidence for their efficacy in COVID-19 [170,230,231] and further studies are needed before giving public messages [170,231,232] in order to avoid potential adverse effects of CAM [232]. It has been reported that Chinese migrant women with GDM were more prone to supplementation use compared with Australian-born white women [233]. On the other hand, a cross-sectional study reported that many pregnant US women were at risk of excessive intake of iron and folic acid, despite others not meeting the recommendations for micronutrients even with the use of supplements [234]. In this context, the position of the Academy of Nutrition and Dietetics is that although pregnant women are among the individuals at particular risk for inadequate dietary intakes of micronutrients, the routine and indiscriminate use of supplements for the prevention of chronic disease is not recommended [235]. More studies are needed in order to evaluate the use of complementary medicine during pregnancy for treating pregnancy-induced nausea [236] and mood status [237]. The former can be due to ketosis [30] and the latter can be increased by lockdown [57,58,60,238].

Psychological stress was among the most common factors to worsen hyperglycemia, followed by changes in diet and exercise, and some patients required additional medications for the control of blood glucose during lockdown [57]. Therefore, the previously suggested multi-level approaches to assist individuals in adapting their health behaviors to prevent both chronic and infectious diseases [239] should be applied to pregnant women.

From the reviewed evidence in this work, it can be concluded that adhering to the MedDiet prior to and during pregnancy could be the better approach to reduce GDM risk and improve immune function. An early MedDiet plan is useful for both mother and offspring in order to reduce composite materno-fetal adverse outcomes [240]. Moreover, a lifestyle that includes physical exercise beyond diet could also promote a better control of weight gain and reduce waist circumference [241]. Therefore, the MedDiet could be considered a useful dietary option during pregnancy.

Author Contributions: Conceptualization, I.P., A.L.F. and A.S.; writing—Original draft preparation, A.L.F. and A.S.; writing—Review and editing, M.M., A.R. and E.T.; supervision, I.P. and P.D.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: We thank Claudio Andrew Gobbi for English review of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ACE	Angiotensin-Converting Enzyme
AGE	Advanced Glycation End Products
ARDS	Acute Respiratory Distress Syndrome
ARE	Antioxidant Responsive Element
BMI	Body Mass Index
CMFCs	Composite of Materno-Fetal Outcomes
CAM	Complementary / Alternative Medicine
COVID-19	Coronavirus Disease 2019
CRP	C-Reactive Protein
CVD	CardioVascular Disease
DASH	Dietary Approaches to Stop Hypertension
DHA	Docosahexaenoic Acid
EVOO	Extra Virgin Olive Oil
GDM	Gestational Diabetes Mellitus
GLUT	Glucose Transporter
GWG	Gestational Weight Gain
HbA1c	Glycated Hemoglobin
HOMA-IR	Homeostasis Model Assessment of Insulin Resistance
IFN	Interferon
I- κ B	Kappa b inhibitor
IL	Interleukin
KEAP1	Kelch-Like ECH-Associated Protein 1
LPS	Lipopolysaccharide
MAPK	Mitogen-Activated Protein Kinases
MedDiet	Mediterranean Diet
MetSyn	Metabolic Syndrome
NF- κ	Nuclear Factor Kappa
Nrf2	Nuclear Factor Erythroid-Derived 2-Like
omega-3 PUFA	Omega-3 Polyunsaturated Fatty Acids
RAGE	Receptor for Advanced Glycation End-Products
ROS	Reactive Oxygen Species
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
SAT	Subcutaneous Adipose Tissue
SCFA	Short-Chain Fatty Acids
SGA	Small-For-Gestational-Age
T2D	Type 2 Diabetes
Th	T Helper
TLR	Toll Like Receptor
TNF	Tumor Necrosis Factor
VAT	Visceral Adipose Tissue

References

- Center for System Science and Engineering. COVID-19. 2020. Available online: <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6> (accessed on 29 November 2020).
- Mattioli, A.; Puviani, M.B.; Nasi, M.; Farinetti, A. COVID-19 pandemic: The effects of quarantine on cardiovascular risk. *Eur. J. Clin. Nutr.* **2020**, *74*, 852–855. [[CrossRef](#)] [[PubMed](#)]
- Katz, D.L. Leveraging the exit of diabesity: We suffer from obesity and diabetes because we eat too much and exercise too little. Solving the problem is hard but not complicated. *IEEE Pulse* **2014**, *5*, 18–21. [[CrossRef](#)]
- Riobo Servan, P. Obesity and diabetes. *Nutr. Hosp.* **2013**, *28* (Suppl. 5), 138–143. [[CrossRef](#)] [[PubMed](#)]
- Kalra, S. Diabesity. In *J. Pak. Med. Assoc.*; 2013; 63, pp. 532–534. Available online: <http://www.ncbi.nlm.nih.gov/pubmed/23905459> (accessed on 29 November 2020). [[PubMed](#)]
- Franquesa, M.; Pujol-Busquets, G.; García-Fernández, E.; Rico, L.; Shamirian-Pulido, L.; Aguilar-Martínez, A.; Medina, F.-X.; Serra-Majem, L.; Bach-Faig, A. Mediterranean Diet and Cardiodiabesity: A Systematic Review through Evidence-Based Answers to Key Clinical Questions. *Nutrients* **2019**, *11*, 655. [[CrossRef](#)] [[PubMed](#)]
- García-Fernández, E.; Rico-Cabanas, L.; Rosgaard, N.; Estruch, R.; Bach-Faig, A. Mediterranean diet and cardiodiabesity: A review. *Nutrients* **2014**, *6*, 3474–3500. [[CrossRef](#)]

8. Emami, A.; Javanmardi, F.; Pirbonyeh, N.; Akbari, A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. In *Arch. Acad. Emerg. Med.*; 2020; 8, p. e35. Available online: <http://www.ncbi.nlm.nih.gov/pubmed/32232218> (accessed on 29 November 2020).
9. Zabetakis, I.; Lordan, R.; Norton, C.; Tsoupras, A. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation. *Nutrients* **2020**, *12*, 1466. [[CrossRef](#)]
10. Martinez-Ferran, M.; De La Guía-Galipienso, F.; Sanchis-Gomar, F.; Pareja-Galeano, H. Metabolic Impacts of Confinement during the COVID-19 Pandemic Due to Modified Diet and Physical Activity Habits. *Nutrients* **2020**, *12*, 1549. [[CrossRef](#)]
11. Hartmann-Boyce, J.; Morris, E.; Goyder, C.; Kinton, J.; Perring, J.; Nunan, D.; Mahtani, K.; Buse, J.B.; Del Prato, S.; Ji, L.; et al. Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. *Diabetes Care* **2020**, *43*, 1695–1703. [[CrossRef](#)]
12. Frydrych, L.M.; Bian, G.; O’Lone, D.E.; Ward, P.A.; Delano, M.J. Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. *J. Leukoc. Biol.* **2018**, *104*, 525–534. [[CrossRef](#)] [[PubMed](#)]
13. Bloomgarden, Z.T. Diabetes and COVID-19. *J. Diabetes* **2020**, *12*, 347–348. [[CrossRef](#)] [[PubMed](#)]
14. Gleeson, L.E.; Roche, H.M.; Sheedy, F.J. Obesity, COVID-19 and innate immunometabolism. *Br. J. Nutr.* **2020**, 1–5. [[CrossRef](#)]
15. Morais, A.H.D.A.; Aquino, J.D.S.; Da Silva-Maia, J.K.; Vale, S.H.L.; Maciel, B.L.L.; Passos, T.S. Nutritional status, diet and viral respiratory infections: Perspectives for severe acute respiratory syndrome coronavirus 2. *Br. J. Nutr.* **2020**, 1–12. [[CrossRef](#)] [[PubMed](#)]
16. Chari, A.; Bendriss, G.; Zakaria, D.; McVeigh, C. Importance of Dietary Changes During the Coronavirus Pandemic: How to Upgrade Your Immune Response. *Front. Public Health* **2020**, *8*, 476. [[CrossRef](#)]
17. FDA. Available online: <https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19> (accessed on 29 November 2020).
18. FDA. Available online: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19> (accessed on 29 November 2020).
19. FDA. Available online: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs> (accessed on 29 November 2020).
20. Borges do Nascimento, I.J.; Von Groote, T.C.; O’Mathuna, D.P.; Abdulazeem, H.M.; Henderson, C.; Jayarajah, U.; Weerasekara, I.; Poklepovic Pericic, T.; Klapproth, H.E.G.; Puljak, L.; et al. International Task Force Network of Coronavirus, Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: A systematic review and series of meta-analyses. *PLoS ONE* **2020**, *15*, e0239235. [[CrossRef](#)]
21. Bhadade, R.; Harde, M.; De Souza, R.; Kasbe, A.; Deshpande, C.; Dave, S.; Joshi, M.; Bharmal, R.; Madke, T. Appraisal of Critically Ill COVID-19 Patients at a Dedicated COVID Hospital. In *J. Assoc. Physicians India*; 2020; 68, pp. 14–19. Available online: <http://www.ncbi.nlm.nih.gov/pubmed/32798339> (accessed on 29 November 2020).
22. Di Mascio, D. COVID, Maternal and Perinatal Outcomes of Pregnant Women with SARS-COV-2 infection. *Ultrasound. Obstet. Gynecol.* **2020**. [[CrossRef](#)]
23. Mendoza, M.; Garcia-Ruiz, I.; Maiz, N.; Rodo, C.; Garcia-Manau, P.; Serrano, B.; Lopez-Martinez, R.M.; Balcells, J.; Fernandez-Hidalgo, N.; Carreras, E.; et al. Pre-eclampsia-like syndrome induced by severe COVID-19: A prospective observational study. *BJOG* **2020**, *127*, 1374–1380. [[CrossRef](#)]
24. Elkafrawi, D.; Joseph, J.; Schiattarella, A.; Rodriguez, B.; Sisti, G. Intrauterine transmission of COVID-19 in Pregnancy: Case report and review of literature. *Acta Biomed.* **2020**, *91*, e2020041. [[CrossRef](#)]
25. Raveendran, A.V.; Chacko, E.C.; Pappachan, J.M. Non-pharmacological Treatment Options in the Management of Diabetes Mellitus. *Eur. Endocrinol.* **2018**, *14*, 31–39. [[CrossRef](#)] [[PubMed](#)]
26. Hannan, M.A.; Rahman, M.A.; Rahman, M.S.; Sohag, A.A.M.; Dash, R.; Hossain, K.S.; Farjana, M.; Uddin, M.J. Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response. *Immunol. Lett.* **2020**, *226*, 38–45. [[CrossRef](#)] [[PubMed](#)]
27. Soliman, S.; Faris, M.E.; Ratemi, Z.; Halwani, R. Switching Host Metabolism as an Approach to Dampen SARS-CoV-2 Infection. *Ann. Nutr. Metab.* **2020**, 1–7. [[CrossRef](#)]
28. Sukkar, S.G.; Bassetti, M. Induction of ketosis as a potential therapeutic option to limit hyperglycemia and prevent cytokine storm in COVID-19. *Nutrition* **2020**. [[CrossRef](#)]
29. Bradshaw, P.C.; Seeds, W.A.; Miller, A.C.; Mahajan, V.R.; Curtis, W.M. COVID-19: Proposing a Ketone-Based Metabolic Therapy as a Treatment to Blunt the Cytokine Storm. *Oxid. Med. Cell Longev.* **2020**, *2020*, 6401341. [[CrossRef](#)]
30. Albert, L.; Capel, I.; García-Sáez, G.; Martín-Redondo, P.; Hernando, M.E.; Rigla, M. Managing gestational diabetes mellitus using a smartphone application with artificial intelligence (SineDie) during the COVID-19 pandemic: Much more than just telemedicine. *Diabetes Res. Clin. Pract.* **2020**, *169*, 108396. [[CrossRef](#)]
31. Maiorino, M.I.; Bellastella, G.; Longo, M.; Caruso, P.; Esposito, K. Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes. *Front. Endocrinol.* **2020**, *11*, 574315. [[CrossRef](#)]
32. Angelidi, A.M.; Kokkinos, A.; Katechaki, E.; Ros, E.; Mantzoros, C.S. Mediterranean diet as a nutritional approach for COVID-19. *Metabolism* **2020**, 154407. [[CrossRef](#)]
33. Tsoupras, A.; Lordan, R.; Zabetakis, I. Thrombosis and COVID-19: The Potential Role of Nutrition. *Front. Nutr.* **2020**, *7*, 583080. [[CrossRef](#)]

34. Pasquarelli-Do-Nascimento, G.; Braz-De-Melo, H.A.; Faria, S.S.; Santos, I.D.O.; Kobinger, G.P.; Magalhães, K.G. Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. *Front. Endocrinol.* **2020**, *11*, 530. [[CrossRef](#)]
35. Zhong, Y.; Cao, Y.; Zhong, X.; Peng, Z.; Jiang, S.; Tang, T.; Chen, H.; Li, X.; Xia, Y.; Cheng, Y.; et al. Immunity and Coagulation/Fibrinolytic Processes may Reduce the Risk of Severe Illness in Pregnant Women with COVID-19. *Am. J. Obstet. Gynecol.* **2020**. [[CrossRef](#)] [[PubMed](#)]
36. Turan, O.; Hakim, A.; Dashraath, P.; Jeslyn, W.J.L.; Wright, A.; Abdul-Kadir, R. Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review. *Int. J. Gynaecol. Obstet.* **2020**. [[CrossRef](#)] [[PubMed](#)]
37. Simoes, E.S.A.C.; Leal, C.R.V. Is SARS-CoV-2 Vertically Transmitted? *Front. Pediatr.* **2020**, *8*, 276. [[CrossRef](#)] [[PubMed](#)]
38. Liu, P.; Zheng, J.; Yang, P.; Wang, X.; Wei, C.; Zhang, S.; Feng, S.; Lan, J.; He, B.; Zhao, D.; et al. The immunologic status of newborns born to SARS-CoV-2-infected mothers in Wuhan, China. *J. Allergy Clin. Immunol.* **2020**, *146*, 101–109. [[CrossRef](#)] [[PubMed](#)]
39. Sarvas, J.L.; Khaper, N.; Lees, S.J. The IL-6 Paradox: Context Dependent Interplay of SOCS3 and AMPK. *J. Diabetes Metab.* **2013**, *1* (Suppl. 13). [[CrossRef](#)] [[PubMed](#)]
40. Senn, J.J.; Klover, P.J.; Nowak, I.A.; Mooney, R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. *Diabetes* **2002**, *51*, 3391–3399. [[CrossRef](#)]
41. Kumar, P.A.; Chitra, P.S.; Lu, C.; Sobhanaditya, J.; Menon, R. Growth hormone (GH) differentially regulates NF- κ B activity in preadipocytes and macrophages: Implications for GH's role in adipose tissue homeostasis in obesity. *J. Physiol. Biochem.* **2014**, *70*, 433–440. [[CrossRef](#)] [[PubMed](#)]
42. Kim, J.H.; Bachmann, R.A.; Chen, J. Interleukin-6 and insulin resistance. *Vitam Horm.* **2009**, *80*, 613–633. [[CrossRef](#)]
43. Morisset, A.-S.; Dubé, M.-C.; Côté, J.A.; Robitaille, J.; Weisnagel, S.J.; Tchernof, A. Circulating interleukin-6 concentrations during and after gestational diabetes mellitus. *Acta Obstet Gynecol. Scand.* **2011**, *90*, 524–530. [[CrossRef](#)]
44. Bari, M.F.; Weickert, M.O.; Sivakumar, K.; James, S.G.; Snead, D.R.J.; Tan, B.K.; Randevara, H.S.; Bastie, C.C.; Vatish, M. Elevated soluble CD163 in gestational diabetes mellitus: Secretion from human placenta and adipose tissue. *PLoS ONE* **2014**, *9*, e101327. [[CrossRef](#)]
45. Sotos-Prieto, M.; Moreno-Franco, B.; Ordovás, J.M.; León, M.; A Casasnovas, J.; Peñalvo, J.L. Design and development of an instrument to measure overall lifestyle habits for epidemiological research: The Mediterranean Lifestyle (MEDLIFE) index. *Public Health Nutr.* **2015**, *18*, 959–967. [[CrossRef](#)] [[PubMed](#)]
46. Ciccotti, M.; Raguzzini, A.; Sciarra, T.; Catasta, G.; Aiello, P.; Buccolieri, C.; Reggi, R.; Palmery, M.; Lista, F.; Peluso, I. Nutraceutical-based Integrative Medicine: Adopting a Mediterranean Diet Pyramid for Attaining Healthy Ageing in Veterans with Disabilities. *Curr. Pharm. Des.* **2018**, *24*, 4186–4196. [[CrossRef](#)] [[PubMed](#)]
47. Aranceta-Bartrina, J.; Partearroyo, T.; López-Sobaler, A.M.; Ortega, R.M.; Varela-Moreiras, G.; Serra-Majem, L.; Pérez-Rodrigo, C. Collaborative Group for the Dietary Guidelines for the Spanish Population (SENC). Updating the Food-Based Dietary Guidelines for the Spanish Population: The Spanish Society of Community Nutrition (SENC) Proposal. *Nutrients* **2019**, *11*, 2675. [[CrossRef](#)] [[PubMed](#)]
48. Bernardi, M.; Fedullo, A.L.; Bernardi, E.; Munzi, D.; Peluso, I.; Myers, J.; Lista, F.R.; Sciarra, T. Diet in neurogenic bowel management: A viewpoint on spinal cord injury. *World J. Gastroenterol.* **2020**, *26*, 2479–2497. [[CrossRef](#)]
49. Zupo, R.; Castellana, F.; Sardone, R.; Sila, A.; Giagulli, V.A.; Triggiani, V.; Cincione, R.I.; Giannelli, G.; De Pergola, G. Preliminary Trajectories in Dietary Behaviors during the COVID-19 Pandemic: A Public Health Call to Action to Face Obesity. *Int. J. Environ. Res. Public Health* **2020**, *17*, 7073. [[CrossRef](#)]
50. Mattioli, A.; Sciomer, S.; Cocchi, C.; Maffei, S.; Gallina, S. Quarantine during COVID-19 outbreak: Changes in diet and physical activity increase the risk of cardiovascular disease. *Nutr. Metab. Cardiovasc. Dis.* **2020**, *30*, 1409–1417. [[CrossRef](#)]
51. Pellegrini, M.; Ponzio, V.; Rosato, R.; Scumaci, E.; Goitre, I.; Benso, A.; Belcastro, S.; Crespi, C.; De Michieli, F.; Ghigo, E.; et al. Changes in Weight and Nutritional Habits in Adults with Obesity during the “Lockdown” Period Caused by the COVID-19 Virus Emergency. *Nutrients* **2020**, *12*, 2016. [[CrossRef](#)]
52. Ruiz-Roso, M.B.; Knott-Torcal, C.; Mantilla-Escalante, D.C.; Garcimartín, A.; Sampedro-Núñez, M.; Dávalos, A.; Marazuela, M. COVID-19 Lockdown and Changes of the Dietary Pattern and Physical Activity Habits in a Cohort of Patients with Type 2 Diabetes Mellitus. *Nutrients* **2020**, *12*, 2327. [[CrossRef](#)]
53. Ghosh, A.; Arora, B.; Gupta, R.; Anoop, S.; Misra, A. Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India. *Diabetes Metab. Syndr.* **2020**, *14*, 917–920. [[CrossRef](#)]
54. Munekawa, C.; Hosomi, Y.; Hashimoto, Y.; Okamura, T.; Takahashi, F.; Kawano, R.; Nakajima, H.; Osaka, T.; Okada, H.; Majima, S.; et al. Effect of coronavirus disease 2019 pandemic on the lifestyle and glycemic control in patients with type 2 diabetes: A cross-section and retrospective cohort study. *Endocr. J.* **2020**. [[CrossRef](#)]
55. Sankar, P.; Ahmed, W.N.; Koshy, V.M.; Jacob, R.; Sasidharan, S. Effects of COVID-19 lockdown on type 2 diabetes, lifestyle and psychosocial health: A hospital-based cross-sectional survey from South India. *Diabetes Metab. Syndr.* **2020**, *14*, 1815–1819. [[CrossRef](#)] [[PubMed](#)]
56. Lindsay, K.L.; Buss, C.; Wadhwa, P.D.; Entringer, S. The Effect of a Maternal Mediterranean Diet in Pregnancy on Insulin Resistance is Moderated by Maternal Negative Affect. *Nutrients* **2020**, *12*, 420. [[CrossRef](#)] [[PubMed](#)]

57. Khare, J.; Jindal, S. Observational study on Effect of Lock Down due to COVID 19 on glycemic control in patients with Diabetes: Experience from Central India. *Diabetes Metab. Syndr.* **2020**, *14*, 1571–1574. [[CrossRef](#)] [[PubMed](#)]
58. Ghesquière, L.; Garabedian, C.; Drumez, E.; Lemaître, M.; Cazaubiel, M.; Bengler, C.; Vambergue, A. Effects of COVID-19 pandemic lockdown on gestational diabetes mellitus: A retrospective study. *Diabetes Metab.* **2020**. [[CrossRef](#)]
59. D'Ambrosi, F.; Rossi, G.; Soldavini, C.M.; Maggi, V.; Cetera, G.E.; Carbone, I.F.; Di Martino, D.; Di Maso, M.; Ferrazzi, E. Management of gestational diabetes in women with a concurrent Sars-Cov-2 infection, experience of a single center in Northern Italy. *Int. J. Gynaecol. Obstet.* **2020**. [[CrossRef](#)]
60. Zhang, J.; Zhang, Y.; Huo, S.; Ma, Y.; Ke, Y.; Wang, P.; Zhao, A. Emotional Eating in Pregnant Women during the COVID-19 Pandemic and Its Association with Dietary Intake and Gestational Weight Gain. *Nutrients* **2020**, *12*, 2250. [[CrossRef](#)]
61. Auguštin, D.H.; Šarac, J.; Lovrić, M.; Živković, J.; Malev, O.; Fuchs, N.; Novokmet, N.; Turkalj, M.; Missoni, S. Adherence to Mediterranean Diet and Maternal Lifestyle during Pregnancy: Island-Mainland Differentiation in the CRIBS Birth Cohort. *Nutrients* **2020**, *12*, 2179. [[CrossRef](#)]
62. Olmedo-Requena, R.; Fernández, J.G.; Prieto, C.A.; Moreno, J.M.; Bueno-Cavanillas, A.; Jiménez-Moleón, J.J. Factors associated with a low adherence to a Mediterranean diet pattern in healthy Spanish women before pregnancy. *Public Health Nutr.* **2014**, *17*, 648–656. [[CrossRef](#)]
63. Biviá-Roig, G.; La Rosa, V.L.; Gómez-Tébar, M.; Serrano-Raya, L.; Amer-Cuenca, J.J.; Caruso, S.; Commodari, E.; Barrasa-Shaw, A.; Lisón, J.F. Analysis of the Impact of the Confinement Resulting from COVID-19 on the Lifestyle and Psychological Wellbeing of Spanish Pregnant Women: An Internet-Based Cross-Sectional Survey. *Int. J. Environ. Res. Public Health* **2020**, *17*, 2933. [[CrossRef](#)]
64. Schoenaker, D.A.J.M.; Soedamah-Muthu, S.S.; Callaway, L.K.; Mishra, G.D. Prepregnancy dietary patterns and risk of developing hypertensive disorders of pregnancy: Results from the Australian Longitudinal Study on Women's Health. *Am. J. Clin. Nutr.* **2015**, *102*, 94–101. [[CrossRef](#)]
65. Li, S.; Zhu, Y.; Chavarro, J.E.; Bao, W.; Tobias, D.K.; Ley, S.H.; Forman, J.P.; Liu, A.; Mills, J.; Bowers, K.; et al. Healthful Dietary Patterns and the Risk of Hypertension Among Women With a History of Gestational Diabetes Mellitus: A Prospective Cohort Study. *Hypertension* **2016**, *67*, 1157–1165. [[CrossRef](#)] [[PubMed](#)]
66. Tobias, D.K.; Hu, F.B.; E Chavarro, J.; Rosner, B.; Mozaffarian, D.; Zhang, C. Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. *Arch. Intern. Med.* **2012**, *172*, 1566–1572. [[CrossRef](#)] [[PubMed](#)]
67. Tobias, D.K.; Zhang, C.; Chavarro, J.E.; Olsen, S.F.; Bao, W.; Bjerregaard, A.A.; Fung, T.T.; Manson, J.E.; Hu, F.B. Healthful dietary patterns and long-term weight change among women with a history of gestational diabetes mellitus. *Int. J. Obes.* **2016**, *40*, 1748–1753. [[CrossRef](#)] [[PubMed](#)]
68. Danser, A.H.J.; Epstein, M.; Batlle, D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. *Hypertension* **2020**, *75*, 1382–1385. [[CrossRef](#)] [[PubMed](#)]
69. Cuschieri, S.; Grech, S. COVID-19 and diabetes: The why, the what and the how. *J. Diabetes Complicat.* **2020**, *34*, 107637. [[CrossRef](#)]
70. Cooper, I.D.; Crofts, C.A.; DiNicolantonio, J.J.; Malhotra, A.; Elliott, B.; Kyriakidou, Y.; Brookler, K.H. Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: Rationale for clinical management. *Open Heart* **2020**, *7*. [[CrossRef](#)]
71. García-Ordás, M.T.; Arias, N.; Benavides, C.; García-Olalla, O.; Benítez-Andrades, J.A. Evaluation of Country Dietary Habits Using Machine Learning Techniques in Relation to Deaths from COVID-19. *Healthcare* **2020**, *8*, 371. [[CrossRef](#)]
72. Marrocco, I.; Altieri, F.; Peluso, I. Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans. *Oxid. Med. Cell Longev.* **2017**, *2017*, 6501046. [[CrossRef](#)]
73. Stillhano, R.S.; Costa, A.J.; Nishino, M.S.; Shams, S.; Bartolomeo, C.S.; Breithaupt-Faloppa, A.C.; Silva, E.A.; Ramirez, A.L.; Prado, C.M.; Ureshino, R.P. SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors. *FASEB J.* **2020**, *34*, 14103–14119. [[CrossRef](#)]
74. Holly, J.M.P.; Biernacka, K.; Maskell, N.; Perks, C.M. Obesity, Diabetes and COVID-19: An Infectious Disease Spreading From the East Collides With the Consequences of an Unhealthy Western Lifestyle. *Front. Endocrinol.* **2020**, *11*, 582870. [[CrossRef](#)]
75. Li, L.; Spranger, L.; Soll, D.; Beer, F.; Brachs, M.; Spranger, J.; Mai, K. Metabolic impact of weight loss induced reduction of adipose ACE-2-Potential implication in COVID-19 infections? *Metabolism* **2020**, *113*, 154401. [[CrossRef](#)] [[PubMed](#)]
76. Dhar, D.; Mohanty, A. Gut microbiota and Covid-19-possible link and implications. *Virus Res.* **2020**, *285*, 198018. [[CrossRef](#)] [[PubMed](#)]
77. Belancic, A. Gut microbiome dysbiosis and endotoxemia-Additional pathophysiological explanation for increased COVID-19 severity in obesity. *Obes. Med.* **2020**, *20*, 100302. [[CrossRef](#)] [[PubMed](#)]
78. Prattichizzo, F.; De Nigris, V.; Spiga, R.; Mancuso, E.; La Sala, L.; Antonicelli, R.; Testa, R.; Procopio, A.D.; Olivieri, F.; Ceriello, A. Inflammaging and metaflammation: The yin and yang of type 2 diabetes. *Ageing Res. Rev.* **2018**, *41*, 1–17. [[CrossRef](#)] [[PubMed](#)]
79. Cani, P.D.; Osto, M.; Geurts, L.; Everard, A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. *Gut Microbes* **2012**, *3*, 279–288. [[CrossRef](#)]
80. Laugerette, F.; Vors, C.; Peretti, N.; Michalski, M. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. *Biochimie* **2011**, *93*, 39–45. [[CrossRef](#)]
81. Dal, S.; Sigrist, S. The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications. *Diseases* **2016**, *4*, 24. [[CrossRef](#)]

82. Peluso, I.; Morabito, G.; Urban, L.; Ioannone, F.; Serafini, M. Oxidative stress in atherosclerosis development: The central role of LDL and oxidative burst. *Endocr. Metab. Immune. Disord. Drug. Targets* **2012**, *12*, 351–360. Available online: <http://www.ncbi.nlm.nih.gov/pubmed/23061409> (accessed on 29 November 2020). [CrossRef]
83. Potenza, M.A.; Nacci, C.; De Salvia, M.A.; Sgarra, L.; Collino, M.; Montagnani, M. Targeting endothelial metaflammation to counteract diabetes cardiovascular risk: Current and perspective therapeutic options. *Pharmacol. Res.* **2017**, *120*, 226–241. [CrossRef]
84. Musso, G.; Paschetta, E.; Gambino, R.; Cassader, M.; Molinaro, F. Interactions among bone, liver, and adipose tissue predisposing to diabetes and fatty liver. *Trends Mol. Med.* **2013**, *19*, 522–535. [CrossRef]
85. Lazar, V.; Ditu, L.-M.; Pircalabioru, G.G.; Picu, A.; Petcu, L.; Cucu, N.; Chifiriuc, M.C. Gut Microbiota, Host Organism, and Diet Triologue in Diabetes and Obesity. *Front. Nutr.* **2019**, *6*, 21. [CrossRef] [PubMed]
86. Khiali, S.; Khani, E.; Entezari-Maleki, T. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. *J. Clin. Pharmacol.* **2020**, *60*, 1131–1146. [CrossRef] [PubMed]
87. Cortegiani, A.; Ippolito, M.; Greco, M.; Granone, V.; Protti, A.; Gregoretto, C.; Giarratano, A.; Einav, S.; Cecconi, M. Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. *Pulmonology* **2021**, *27*, 52–66. [CrossRef] [PubMed]
88. Lan, S.-H.; Lai, C.-C.; Huang, H.-T.; Chang, S.-P.; Lu, L.-C.; Hsueh, P.-R. Tocilizumab for severe COVID-19: A systematic review and meta-analysis. *Int. J. Antimicrob. Agents* **2020**, *56*, 106103. [CrossRef] [PubMed]
89. Antwi-Amoabeng, D.; Kanji, Z.; Ford, B.; Beutler, B.D.; Riddle, M.S.; Siddiqui, F. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. *J. Med. Virol.* **2020**, *92*, 2516–2522. [CrossRef]
90. Zhang, S.; Li, L.; Shen, A.; Chen, Y.; Qi, Z. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. *Clin. Drug Investig.* **2020**, *40*, 511–518. [CrossRef]
91. Bartoli, A.; Gabrielli, F.; Alicandro, T.; Nascimbeni, F.; Andreone, P. COVID-19 treatment options: A difficult journey between failed attempts and experimental drugs. *Intern. Emerg. Med.* **2021**, 1–28. [CrossRef]
92. AIFA. Available online: <https://www.aifa.gov.it/web/guest/-/covid-19-studio-randomizzato-italiano-nessun-beneficio-dal-tocilizumab> (accessed on 29 November 2020).
93. Zhou, B.; Kojima, S.; Kawamoto, A.; Fukushima, M. COVID-19 pathogenesis, prognostic factors and treatment strategy: Urgent recommendations. *J. Med. Virol.* **2020**. [CrossRef]
94. Kim, J.S.; Lee, J.Y.; Yang, J.W.; Lee, K.H.; Effenberger, M.; Szpirt, W.; Kronbichler, A.; Shin, J.I. Immunopathogenesis and treatment of cytokine storm in COVID-19. *Theranostics* **2021**, *11*, 316–329. [CrossRef]
95. Chen, J.-J.; Zhang, L.-N.; Hou, H.; Xu, L.; Ji, K. Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review). *Exp. Ther. Med.* **2020**, *21*, 1. [CrossRef]
96. Liu, D.; Zhang, T.; Wang, Y.; Xia, L. Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? *Front. Med.* **2020**, *7*, 571597. [CrossRef] [PubMed]
97. Berardicurti, O.; Ruscitti, P.; Ursini, F.; D’Andrea, S.; Ciaffi, J.; Meliconi, R.; Iagnocco, A.; Cipriani, P.; Giacomelli, R. Mortality in tocilizumab-treated patients with COVID-19: A systematic review and meta-analysis. *Clin. Exp. Rheumatol.* **2020**, *38*, 1247–1254. [PubMed]
98. Yousefi, H.; Mashouri, L.; Okpechi, S.C.; Alahari, N.; Alahari, S.K. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. *Biochem. Pharmacol.* **2021**, *183*, 114296. [CrossRef] [PubMed]
99. Ucciferri, C.; Vecchiet, J.; Falasca, K. Role of monoclonal antibody drugs in the treatment of COVID-19. *World J. Clin. Cases* **2020**, *8*, 4280–4285. [CrossRef]
100. Hashizume, M. Outlook of IL-6 signaling blockade for COVID-19 pneumonia. *Inflamm. Regen.* **2020**, *40*, 1–8. [CrossRef]
101. Naqvi, M.; Zakowski, P.; Glucksmann, L.; Smithson, S.; Burwick, R.M. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). *Obstet. Gynecol.* **2020**, *136*, 1025–1029. [CrossRef]
102. Oliva, M.; Hsu, K.; Alamarai, S.; De Chavez, V.; Ferrara, L. Clinical improvement of severe COVID-19 pneumonia in a pregnant patient after caesarean delivery. *BMJ Case Rep.* **2020**, *13*, e236290. [CrossRef]
103. McCartney, S.A.; Kachikis, A.; Huebner, E.M.; Walker, C.L.; Chandrasekaran, S.; Waldorf, K.M. Obesity as a contributor to immunopathology in pregnant and non-pregnant adults with COVID. *Am. J. Reprod. Immunol.* **2020**, *84*, e13320. [CrossRef]
104. Pérez-Pérez, A.; Vilariño-García, T.; Guadix, P.; Dueñas-Díez, J.-L.; Sánchez-Margalet, V. Leptin and Nutrition in Gestational Diabetes. *Nutrients* **2020**, *12*, 1970. [CrossRef]
105. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. *JAMA* **2001**, *286*, 327–334. [CrossRef]
106. Akbari, M.; Hassan-Zadeh, V. IL-6 signalling pathways and the development of type 2 diabetes. *Inflammopharmacology* **2018**, *26*, 685–698. [CrossRef] [PubMed]
107. Johns, E.C.; Denison, F.C.; E Norman, J.; Reynolds, R.M. Gestational Diabetes Mellitus: Mechanisms, Treatment, and Complications. *Trends Endocrinol. Metab.* **2018**, *29*, 743–754. [CrossRef] [PubMed]
108. Lekva, T.; Norwitz, E.R.; Aukrust, P.; Ueland, T. Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus. *Curr. Diabetes Rep.* **2016**, *16*, 1–11. [CrossRef] [PubMed]
109. Abell, S.K.; De Courten, B.; Boyle, J.A.; Teede, H. Inflammatory and Other Biomarkers: Role in Pathophysiology and Prediction of Gestational Diabetes Mellitus. *Int. J. Mol. Sci.* **2015**, *16*, 13442–13473. [CrossRef]

110. Hassiakos, D.; Eleftheriades, M.; Papastefanou, I.; Lambrinouadaki, I.; Kappou, D.; Lavranos, D.; Akalestos, A.; Aravantinos, L.; Pervanidou, P.; Chrousos, G. Increased Maternal Serum Interleukin-6 Concentrations at 11 to 14 Weeks of Gestation in Low Risk Pregnancies Complicated with Gestational Diabetes Mellitus: Development of a Prediction Model. *Horm. Metab. Res.* **2015**, *48*, 35–41. [[CrossRef](#)]
111. Nikolajczyk, B.S.; Jagannathan-Bogdan, M.; Denis, G.V. The outliers become a stampede as immunometabolism reaches a tipping point. *Immunol. Rev.* **2012**, *249*, 253–275. [[CrossRef](#)]
112. Zhou, H.; Liu, F. Regulation, Communication, and Functional Roles of Adipose Tissue-Resident CD4+ T Cells in the Control of Metabolic Homeostasis. *Front. Immunol.* **2018**, *9*. [[CrossRef](#)]
113. McLaughlin, T.; Liu, L.-F.; Lamendola, C.; Shen, L.; Morton, J.; Rivas, H.; Winer, D.; Tolentino, L.; Choi, O.; Zhang, H.; et al. T-Cell Profile in Adipose Tissue Is Associated With Insulin Resistance and Systemic Inflammation in Humans. *Arter. Thromb. Vasc. Biol.* **2014**, *34*, 2637–2643. [[CrossRef](#)]
114. Cinkajzlová, A.; Anderlová, K.; Šimják, P.; Lacinová, Z.; Kloučková, J.; Kratochvílová, H.; Krejčí, H.; Pařízek, A.; Mráz, M.; Kršek, M.; et al. Subclinical inflammation and adipose tissue lymphocytes in pregnant females with gestational diabetes mellitus. *J. Clin. Endocrinol. Metab.* **2020**, *105*. [[CrossRef](#)]
115. Alves, J.G.B.; Souza, A.S.R.; Figueiroa, J.N.; De Araújo, C.A.L.; Guimaraes, A.; Ray, J.G. Visceral Adipose Tissue Depth in Early Pregnancy and Gestational Diabetes Mellitus—A Cohort Study. *Sci. Rep.* **2020**, *10*, 2032–2034. [[CrossRef](#)]
116. Teixeira-Lemos, E.; Nunes, S.; Teixeira, F.; Reis, F. Regular physical exercise training assists in preventing type 2 diabetes development: Focus on its antioxidant and anti-inflammatory properties. *Cardiovasc. Diabetol.* **2011**, *10*, 12. [[CrossRef](#)] [[PubMed](#)]
117. Covarrubias, A.J.; Horng, T. IL-6 Strikes a Balance in Metabolic Inflammation. *Cell Metab.* **2014**, *19*, 898–899. [[CrossRef](#)] [[PubMed](#)]
118. Mauer, J.; Chaurasia, B.; Goldau, J.; Vogt, M.C.; Ruud, J.; Nguyen, K.D.; Theurich, S.; Hausen, A.C.; Schmitz, J.; Brönneke, H.S.; et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. *Nat. Immunol.* **2014**, *15*, 423–430. [[CrossRef](#)] [[PubMed](#)]
119. Lauzon-Joset, J.-F.; Scott, N.M.; Mincham, K.T.; Stumbles, P.A.; Holt, P.G.; Strickland, D.H. Pregnancy Induces a Steady-State Shift in Alveolar Macrophage M1/M2 Phenotype That Is Associated With a Heightened Severity of Influenza Virus Infection: Mechanistic Insight Using Mouse Models. *J. Infect. Dis.* **2018**, *219*, 1823–1831. [[CrossRef](#)] [[PubMed](#)]
120. Jena, M.K.; Nayak, N.; Chen, K.; Nayak, N.R. Role of Macrophages in Pregnancy and Related Complications. *Arch. Immunol. Ther. Exp.* **2019**, *67*, 295–309. [[CrossRef](#)] [[PubMed](#)]
121. Ma, Y.; Ye, Y.; Zhang, J.; Ruan, C.-C.; Gao, P.-J. Immune imbalance is associated with the development of preeclampsia. *Medicina* **2019**, *98*, e15080. [[CrossRef](#)] [[PubMed](#)]
122. Xie, L.; Zhang, K.; Rasmussen, D.; Wang, J.; Wu, D.; Roemmich, J.N.; Bundy, A.; Johnson, W.T.; Claycombe, K. Effects of prenatal low protein and postnatal high fat diets on visceral adipose tissue macrophage phenotypes and IL-6 expression in Sprague Dawley rat offspring. *PLoS ONE* **2017**, *12*, e0169581. [[CrossRef](#)]
123. Santesso, N.; Akl, E.; Bianchi, M.L.P.; Mente, A.; Mustafa, R.; Heelsandsell, D.; Schunemann, H.J. Effects of higher- versus lower-protein diets on health outcomes: A systematic review and meta-analysis. *Eur. J. Clin. Nutr.* **2012**, *66*, 780–788. [[CrossRef](#)]
124. David, L.A.; Maurice, C.F.; Carmody, R.N.; Gootenberg, D.B.; Button, J.E.; Wolfe, B.E.; Ling, A.V.; Devlin, A.S.; Varma, Y.; Fischbach, M.A.; et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nat. Cell Biol.* **2014**, *505*, 559–563. [[CrossRef](#)]
125. Blachier, F.; Beaumont, M.; Portune, K.J.; Steuer, N.; Lan, A.; Audebert, M.; Khodorova, N.; Andriamihaja, M.; Airinei, G.; Benamouzig, R.; et al. High-protein diets for weight management: Interactions with the intestinal microbiota and consequences for gut health. A position paper by the my new gut study group. *Clin. Nutr.* **2019**, *38*, 1012–1022. [[CrossRef](#)]
126. Tagliabue, A.; Ferraris, C.; Uggeri, F.; Trentani, C.; Bertoli, S.; De Giorgis, V.; Veggiotti, P.; Elli, M. Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational study. *Clin. Nutr. ESPEN* **2017**, *17*, 33–37. [[CrossRef](#)] [[PubMed](#)]
127. Sainsbury, E.; Kizirian, N.V.; Partridge, S.R.; Gill, T.; Colagiuri, S.; Gibson, A.A. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis. *Diabetes Res. Clin. Pract.* **2018**, *139*, 239–252. [[CrossRef](#)] [[PubMed](#)]
128. Caprio, M.; Infante, M.; Moriconi, E.; Armani, A.; Fabbri, A.; Mantovani, G.; Mariani, S.; Lubrano, C.; Poggiogalle, E.; Cardiovascular Endocrinology Club of the Italian Society of Endocrinology; et al. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: Systematic review and consensus statement from the Italian Society of Endocrinology (SIE). *J. Endocrinol. Investig.* **2019**, *42*, 1365–1386. [[CrossRef](#)] [[PubMed](#)]
129. Ajala, O.; English, P.; Pinkney, J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. *Am. J. Clin. Nutr.* **2013**, *97*, 505–516. [[CrossRef](#)] [[PubMed](#)]
130. Huo, R.; Du, T.; Xu, Y.; Xu, W.; Chen, X.; Sun, K.; Yu, X. Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: A meta-analysis. *Eur. J. Clin. Nutr.* **2014**, *69*, 1200–1208. [[CrossRef](#)]
131. Butler, M.J.; Barrientos, R.M. The impact of nutrition on COVID-19 susceptibility and long-term consequences. *Brain, Behav. Immun.* **2020**, *87*, 53–54. [[CrossRef](#)]
132. Giannakou, K.; Evangelou, E.; Yiallourous, P.; Christophi, C.A.; Middleton, N.; Papatheodorou, E.; Papatheodorou, S.I. Risk factors for gestational diabetes: An umbrella review of meta-analyses of observational studies. *PLoS ONE* **2019**, *14*, e0215372. [[CrossRef](#)]
133. Xu, X.; Liu, Y.; Liu, D.; Li, X.; Rao, Y.; Sharma, M.; Zhao, Y. Prevalence and Determinants of Gestational Diabetes Mellitus: A Cross-Sectional Study in China. *Int. J. Environ. Res. Public Health* **2017**, *14*, 1532. [[CrossRef](#)]

134. Christian, L.M.; Porter, K. Longitudinal changes in serum proinflammatory markers across pregnancy and postpartum: Effects of maternal body mass index. *Cytokine* **2014**, *70*, 134–140. [[CrossRef](#)]
135. Challis, J.R.; Lockwood, C.J.; Myatt, L.; Norman, J.E.; Strauss, I.J.F.; Petraglia, F. Inflammation and Pregnancy. *Reprod. Sci.* **2009**, *16*, 206–215. [[CrossRef](#)]
136. Hajianfar, H.; Esmailzadeh, A.; Feizi, A.; Shahshahan, Z.; Azadbakht, L. The Association Between Major Dietary Patterns and Pregnancy-related Complications. *Arch. Iran. Med.* **2018**, *21*, 443–451.
137. Izadi, V.; Tehrani, H.; Haghghatdoost, F.; Dehghan, A.; Surkan, P.J.; Azadbakht, L. Adherence to the DASH and Mediterranean diets is associated with decreased risk for gestational diabetes mellitus. *Nutrition* **2016**, *32*, 1092–1096. [[CrossRef](#)] [[PubMed](#)]
138. Mijatovic-Vukas, J.; Capling, L.; Cheng, S.; Stamatakis, E.; Louie, J.C.Y.; Cheung, N.W.; Markovic, T.P.; Ross, G.; Senior, A.M.; Brand-Miller, J.; et al. Associations of Diet and Physical Activity with Risk for Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Nutrients* **2018**, *10*, 698. [[CrossRef](#)] [[PubMed](#)]
139. Donazar-Ezcurra, M.; Burgo, C.L.-D.; Martínez-González, M.A.; Basterra-Gortari, F.J.; De Irala, J.; Bes-Rastrollo, M. Pre-pregnancy adherences to empirically derived dietary patterns and gestational diabetes risk in a Mediterranean cohort: The Seguimiento Universidad de Navarra (SUN) project. *Br. J. Nutr.* **2017**, *118*, 715–721. [[CrossRef](#)] [[PubMed](#)]
140. Yamauchi, T.; Kamiya, H.; Utsunomiya, K.; Watada, H.; Kawanami, D.; Sato, J.; Kitada, M.; Koya, D.; Harada, N.; Shide, K.; et al. Medical nutrition therapy and dietary counseling for patients with diabetes-energy, carbohydrates, protein intake and dietary counseling. *Diabetol. Int.* **2020**, *11*, 1–16. [[CrossRef](#)]
141. Assaf-Balut, C.; De La Torre, N.G.; Durán, A.; Fuentes, M.; Bordiú, E.; Del Valle, L.; Familiar, C.; Ortolá, A.; Jiménez, I.; Herraiz, M.A.; et al. A Mediterranean diet with additional extra virgin olive oil and pistachios reduces the incidence of gestational diabetes mellitus (GDM): A randomized controlled trial: The St. Carlos GDM prevention study. *PLoS ONE* **2017**, *12*, e0185873. [[CrossRef](#)]
142. Al Wattar, B.H.; Dodds, J.; Placzek, A.; Beresford, L.; Spyreli, E.; Moore, A.; Carreras, F.J.G.; Austin, F.; Murugesu, N.; Roseboom, T.J.; et al. Mediterranean-style diet in pregnant women with metabolic risk factors (ESTEEM): A pragmatic multicentre randomised trial. *PLoS Med.* **2019**, *16*, e1002857. [[CrossRef](#)]
143. Cano-Ibáñez, N.; Martínez-Galiano, J.M.; Luque-Fernandez, M.A.; Martín-Peláez, S.; Bueno-Cavanillas, A.; Delgado-Rodríguez, M. Maternal Dietary Patterns during Pregnancy and Their Association with Gestational Weight Gain and Nutrient Adequacy. *Int. J. Environ. Res. Public Health* **2020**, *17*, 7908. [[CrossRef](#)]
144. Renault, K.M.; Carlsen, E.M.; Nørgaard, K.; Nilas, L.; Pryds, O.; Secher, N.J.; Olsen, S.F.; Halldorsson, T.I. Intake of Sweets, Snacks and Soft Drinks Predicts Weight Gain in Obese Pregnant Women: Detailed Analysis of the Results of a Randomised Controlled Trial. *PLoS ONE* **2015**, *10*, e0133041. [[CrossRef](#)]
145. Koutelidakis, A.E.; Alexatou, O.; Kousaiti, S.; Gkretsi, E.; Vasios, G.; Sampani, A.; Tolia, M.; Kiortsis, D.N.; Giaginis, C. Higher adherence to Mediterranean diet prior to pregnancy is associated with decreased risk for deviation from the maternal recommended gestational weight gain. *Int. J. Food Sci. Nutr.* **2018**, *69*, 84–92. [[CrossRef](#)]
146. Valle, M.A.S.-D.; Sánchez-Villegas, A.; Serra-Majem, L. Association between the adherence to the Mediterranean diet and overweight and obesity in pregnant women in Gran Canaria. *Nutr. Hosp.* **2013**, *28*, 654–659.
147. Assaf-Balut, C.; De La Torre, N.G.; Calle-Pascual, A.L.; Durán, A.; Jiménez, I.; Rubio, M.Á.; Herraiz, M.Á.; Izquierdo, N.; Pérez, N.; Garcia, A.S.; et al. Detection, treatment and prevention programs for gestational diabetes mellitus: The St Carlos experience. *Endocrinol. Diabetes Nutr.* **2020**, *67*, 342–350. [[CrossRef](#)] [[PubMed](#)]
148. De La Torre, N.G.; Assaf-Balut, C.; Jiménez, I.; Del Valle, L.; Durán, A.; Fuentes, M.; Del Prado, N.; Bordiú, E.; Valerio, J.D.; A Herraiz, M.; et al. Effectiveness of Following Mediterranean Diet Recommendations in the Real World in the Incidence of Gestational Diabetes Mellitus (GDM) and Adverse Maternal-Foetal Outcomes: A Prospective, Universal, Interventional Study with a Single Group. The St Carlos Study. *Nutrients* **2019**, *11*, 1210. [[CrossRef](#)]
149. Melero, V.; Assaf-Balut, C.; De La Torre, N.G.; Jiménez, I.; Bordiú, E.; Del Valle, L.; Valerio, J.D.; Familiar, C.; Durán, A.; Runkle, I.; et al. Benefits of Adhering to a Mediterranean Diet Supplemented with Extra Virgin Olive Oil and Pistachios in Pregnancy on the Health of Offspring at 2 Years of Age. Results of the San Carlos Gestational Diabetes Mellitus Prevention Study. *J. Clin. Med.* **2020**, *9*, 1454. [[CrossRef](#)]
150. Assaf-Balut, C.; De La Torre, N.G.; Fuentes, M.; Durán, A.; Bordiú, E.; Del Valle, L.; Valerio, J.D.; Jiménez, I.; A Herraiz, M.; Izquierdo, N.; et al. A High Adherence to Six Food Targets of the Mediterranean Diet in the Late First Trimester is Associated with a Reduction in the Risk of Materno-Foetal Outcomes: The St. Carlos Gestational Diabetes Mellitus Prevention Study. *Nutrients* **2018**, *11*, 66. [[CrossRef](#)]
151. Olmedo-Requena, R.; Gómez-Fernández, J.; Amezcua-Prieto, C.; Mozas-Moreno, J.; Khan, K.S.; Jiménez-Moleón, J.J. Pre-Pregnancy Adherence to the Mediterranean Diet and Gestational Diabetes Mellitus: A Case-Control Study. *Nutrients* **2019**, *11*, 1003. [[CrossRef](#)]
152. Karamanos, B.; Thanopoulou, A.; Anastasiou, E.; Assaad-Khalil, S.; Albache, N.; Bachaoui, M.; Slama, C.B.; El Ghomari, H.; Jotic, A.; MGSD-GDM Study Group; et al. Relation of the Mediterranean diet with the incidence of gestational diabetes. *Eur. J. Clin. Nutr.* **2013**, *68*, 8–13. [[CrossRef](#)]
153. Lappas, M. Activation of inflammasomes in adipose tissue of women with gestational diabetes. *Mol. Cell. Endocrinol.* **2014**, *382*, 74–83. [[CrossRef](#)]

154. Assaf-Balut, C.; De La Torre, N.G.; Durán, A.; Fuentes, M.; Bordiú, E.; Del Valle, L.; Valerio, J.; Familiar, C.; Jiménez, I.; Herraiz, M.A.; et al. Medical nutrition therapy for gestational diabetes mellitus based on Mediterranean Diet principles: A subanalysis of the St Carlos GDM Prevention Study. *BMJ Open Diabetes Res. Care* **2018**, *6*, e000550. [[CrossRef](#)]
155. Assaf-Balut, C.; De La Torre, N.G.; Durán, A.; Bordiú, E.; Del Valle, L.; Familiar, C.; Valerio, J.D.; Jiménez, I.; Herraiz, M.A.; Izquierdo, N.; et al. An Early, Universal Mediterranean Diet-Based Intervention in Pregnancy Reduces Cardiovascular Risk Factors in the “Fourth Trimester”. *J. Clin. Med.* **2019**, *8*, 1499. [[CrossRef](#)]
156. Mari-Sanchis, A.; Díaz-Jurado, G.; Basterra-Gortari, F.J.; De La Fuente-Arrillaga, C.; Martínez-González, M.A.; Bes-Rastrollo, M. Association between pre-pregnancy consumption of meat, iron intake, and the risk of gestational diabetes: The SUN project. *Eur. J. Nutr.* **2017**, *57*, 939–949. [[CrossRef](#)] [[PubMed](#)]
157. Donazar-Ezcurra, M.; Burgo, C.L.-D.; Martínez-González, M.A.; Basterra-Gortari, F.J.; De Irala, J.; Bes-Rastrollo, M. Soft drink consumption and gestational diabetes risk in the SUN project. *Clin. Nutr.* **2018**, *37*, 638–645. [[CrossRef](#)] [[PubMed](#)]
158. Pereira-Da-Silva, L.; Pinto, E. Low Adherence to Mediterranean Diet in Portugal: Pregnant Women Nutrition in Portugal and its Repercussions. *Acta Médica Port.* **2016**, *29*, 658–666. [[CrossRef](#)] [[PubMed](#)]
159. Mingot, D.L.; Gesteiro, E.; Bastida, S.; Sánchez-Muniz, F.J. Epigenetic effects of the pregnancy Mediterranean diet adherence on the offspring metabolic syndrome markers. *J. Physiol. Biochem.* **2017**, *73*, 495–510. [[CrossRef](#)] [[PubMed](#)]
160. Renault, K.M.; Carlsen, E.M.; Nørgaard, K.; Nilas, L.; Pryds, O.; Secher, N.J.; Cortes, D.; Jensen, J.-E.B.; Olsen, S.F.; I Halldorsson, T. Intake of carbohydrates during pregnancy in obese women is associated with fat mass in the newborn offspring. *Am. J. Clin. Nutr.* **2015**, *102*, 1475–1481. [[CrossRef](#)] [[PubMed](#)]
161. Biagi, C.; Di Nunzio, M.; Bordon, A.; Gori, D.; Lanari, M. Effect of Adherence to Mediterranean Diet during Pregnancy on Children’s Health: A Systematic Review. *Nutrients* **2019**, *11*, 997. [[CrossRef](#)]
162. Schoenaker, D.A.J.M.; Soedamah-Muthu, S.S.; Callaway, L.K.; Mishra, G.D. Pre-pregnancy dietary patterns and risk of gestational diabetes mellitus: Results from an Australian population-based prospective cohort study. *Diabetologia* **2015**, *58*, 2726–2735. [[CrossRef](#)]
163. Chatzi, L.; Rifas-Shiman, S.L.; Georgiou, V.; Joung, K.E.; Koinaki, S.; Chalkiadaki, G.; Margioris, A.; Sarri, K.; Vassilaki, M.; Vafeiadi, M.; et al. Adherence to the Mediterranean diet during pregnancy and offspring adiposity and cardiometabolic traits in childhood. *Pediatr. Obes.* **2017**, *12*, 47–56. [[CrossRef](#)]
164. Chatzi, L.; Garcia, R.; Roumeliotaki, T.; Basterrechea, M.; Begiristain, H.; Iñiguez, C.; Vioque, J.; Kogevinas, M.; Sunyer, J. Mediterranean diet adherence during pregnancy and risk of wheeze and eczema in the first year of life: INMA (Spain) and RHEA (Greece) mother–child cohort studies. *Br. J. Nutr.* **2013**, *110*, 2058–2068. [[CrossRef](#)]
165. Zhang, Y.; Lin, J.; Fu, W.; Liu, S.; Gong, C.; Dai, J. Mediterranean diet during pregnancy and childhood for asthma in children: A systematic review and meta-analysis of observational studies. *Pediatr. Pulmonol.* **2019**, *54*, 949–961. [[CrossRef](#)]
166. Verduci, E.; Martelli, A.; Miniello, V.; Landi, M.; Mariani, B.; Brambilla, M.; Diaferio, L.; Peroni, D. Nutrition in the first 1000 days and respiratory health: A descriptive review of the last five years’ literature. *Allergol. Immunopathol.* **2017**, *45*, 405–413. [[CrossRef](#)] [[PubMed](#)]
167. Calder, P.C.; Carr, A.C.; Gombart, A.F.; Eggersdorfer, M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. *Nutrients* **2020**, *12*, 1181. [[CrossRef](#)] [[PubMed](#)]
168. Alkhatib, A. Antiviral Functional Foods and Exercise Lifestyle Prevention of Coronavirus. *Nutrients* **2020**, *12*, 2633. [[CrossRef](#)] [[PubMed](#)]
169. Bourbour, F.; Dahka, S.M.; Gholamalizadeh, M.; Akbari, M.E.; Shadnoush, M.; Haghighi, M.; Taghvaye-Masoumi, H.; Ashoori, N.; Doaei, S. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus. *Arch. Physiol. Biochem.* **2020**, 1–10. [[CrossRef](#)]
170. Richardson, D.P.; Lovegrove, J.A. Nutritional status of micronutrients as a possible and modifiable risk factor for COVID-19: A UK perspective. *Br. J. Nutr.* **2020**, 1–7. [[CrossRef](#)]
171. Aman, F.; Masood, S. How Nutrition can help to fight against COVID-19 Pandemic. *Pak. J. Med. Sci.* **2020**, *36*, S121–S123. [[CrossRef](#)]
172. Coelho-Ravagnani, C.D.F.; Corgosinho, F.C.; Sanches, F.L.F.Z.; Prado, C.M.M.; Laviano, A.; Mota, J.F. Dietary recommendations during the COVID-19 pandemic. *Nutr. Rev.* **2020**. [[CrossRef](#)]
173. Bauer, S.R.; Kapoor, A.; Rath, M.; Thomas, S.A. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? *Clevel. Clin. J. Med.* **2020**. [[CrossRef](#)]
174. Weill, P.; Plissonneau, C.; Legrand, P.; Rioux, V.; Thibault, R. May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? *Biochimie* **2020**, *179*, 275–280. [[CrossRef](#)]
175. Santos, H.O.; Tinsley, G.M.; Da Silva, G.A.R.; Bueno, A.A. Pharmaconutrition in the Clinical Management of COVID-19: A Lack of Evidence-Based Research But Clues to Personalized Prescription. *J. Pers. Med.* **2020**, *10*, 145. [[CrossRef](#)]
176. Rozga, M.; Cheng, F.W.; Moloney, L.; Handu, D. Effects of Micronutrients or Conditional Amino Acids on COVID-19-Related Outcomes: An Evidence Analysis Center Scoping Review. *J. Acad. Nutr. Diet.* **2020**. [[CrossRef](#)]
177. Pecora, F.; Persico, F.; Argentiero, A.; Neglia, C.; Esposito, S. The Role of Micronutrients in Support of the Immune Response against Viral Infections. *Nutrients* **2020**, *12*, 3198. [[CrossRef](#)] [[PubMed](#)]
178. Gasmi, A.; Tippairote, T.; Mujawdiya, P.K.; Peana, M.; Menzel, A.; Dadar, M.; Benahmed, A.G.; Bjørklund, G. Micronutrients as immunomodulatory tools for COVID-19 management. *Clin. Immunol.* **2020**, *220*, 108545. [[CrossRef](#)] [[PubMed](#)]

179. Noor, A.R.; Abioye, A.I.; Darling, A.M.; Hertzmark, E.; Aboud, S.; Premji, Z.; Mugusi, F.M.; Duggan, C.P.; Sudfeld, C.; Spiegelman, D.; et al. Prenatal Zinc and Vitamin A Reduce the Benefit of Iron on Maternal Hematologic and Micronutrient Status at Delivery in Tanzania. *J. Nutr.* **2019**, *150*, 240–248. [[CrossRef](#)]
180. Orru, B.; Szekeres-Bartho, J.; Bizzarri, M.; Spiga, A.M.; Unfer, V. Inhibitory effects of Vitamin D on inflammation and IL-6 release. A further support for COVID-19 management? *Eur. Rev. Med. Pharmacol. Sci.* **2020**, *24*, 8187–8193. [[CrossRef](#)]
181. Wallace, T. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition? *J. Am. Coll. Nutr.* **2020**, *39*, 685–693. [[CrossRef](#)]
182. Motamed, S.; Nikooyeh, B.; Kashanian, M.; Hollis, B.W.; Neyestani, T.R. Efficacy of two different doses of oral vitamin D supplementation on inflammatory biomarkers and maternal and neonatal outcomes. *Matern. Child Nutr.* **2019**, *15*, e12867. [[CrossRef](#)]
183. Rizzo, G.; Garzon, S.; Fichera, M.; Panella, M.; Catena, U.; Schiattarella, A.; De Franciscis, P.; Vilos, G.A.; Tesarik, J.; Török, P.; et al. Vitamin D and Gestational Diabetes Mellitus: Is There a Link? *Antioxidants* **2019**, *8*, 511. [[CrossRef](#)]
184. Griffith, R.J.; Alsweller, J.; Moore, A.E.; Brown, S.; Middleton, P.; Shepherd, E.; Crowther, C.A. Interventions to prevent women from developing gestational diabetes mellitus: An overview of Cochrane Reviews. *Cochrane Database Syst. Rev.* **2020**, *6*, CD012394. [[CrossRef](#)]
185. Massari, M.; Novielli, C.; Chiara, M.; Di Francesco, S.; Della Porta, M.; Cazzola, R.; Panteghini, M.; Savasi, V.; Maggini, S.; Schaefer, E.; et al. Multiple Micronutrients and Docosahexaenoic Acid Supplementation during Pregnancy: A Randomized Controlled Study. *Nutrients* **2020**, *12*, 2432. [[CrossRef](#)]
186. Peluso, I.; Romanelli, L.; Palmery, M. Interactions between prebiotics, probiotics, polyunsaturated fatty acids and polyphenols: Diet or supplementation for metabolic syndrome prevention? *Int. J. Food Sci. Nutr.* **2014**, *65*, 259–267. [[CrossRef](#)] [[PubMed](#)]
187. Schiattarella, A.; Riemma, G.; LaVerde, M.; Franci, G.; Chianese, A.; Fasulo, D.; Fichera, M.; Gallo, P.; DeFranciscis, P. Polycystic Ovary Syndrome and Probiotics: A Natural Approach to an Inflammatory Disease. *Curr. Women's Health Rev.* **2020**. [[CrossRef](#)]
188. Eid, H.M.; Wright, M.L.; Kumar, N.V.A.; Qawasmeh, A.; Hassan, S.T.S.; Mocan, A.; Nabavi, S.M.; Rastrelli, L.; Atanasov, A.G.; Haddad, P.S. Significance of Microbiota in Obesity and Metabolic Diseases and the Modulatory Potential by Medicinal Plant and Food Ingredients. *Front. Pharmacol.* **2017**, *8*, 387. [[CrossRef](#)] [[PubMed](#)]
189. Leri, M.; Scuto, M.; Ontario, M.L.; Calabrese, V.; Calabrese, V.; Bucciantini, M.; Stefani, M. Healthy Effects of Plant Polyphenols: Molecular Mechanisms. *Int. J. Mol. Sci.* **2020**, *21*, 1250. [[CrossRef](#)] [[PubMed](#)]
190. Preuss, H.G. Bean Amylase Inhibitor and Other Carbohydrate Absorption Blockers: Effects on Diabetes and General Health. *J. Am. Coll. Nutr.* **2009**, *28*, 266–276. [[CrossRef](#)] [[PubMed](#)]
191. Chiasson, J.-L.; Josse, R.G.; Gomis, R.; Hanefeld, M.; Karasik, A.; Laakso, M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. *Lancet* **2002**, *359*, 2072–2077. [[CrossRef](#)]
192. Onishi, J.C.; Häggblom, M.; Shapses, S.A. Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations? *mBio* **2020**, *11*. [[CrossRef](#)]
193. Bellavite, P.; Donzelli, A. Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. *Antioxidants* **2020**, *9*, 742. [[CrossRef](#)]
194. Di Matteo, G.; Spano, M.; Grosso, M.; Salvo, A.; Ingallina, C.; Russo, M.; Ritieni, A.; Mannina, L. Food and COVID-19: Preventive/Co-therapeutic Strategies Explored by Current Clinical Trials and in Silico Studies. *Foods* **2020**, *9*, 1036. [[CrossRef](#)]
195. Vijayakumar, B.G.; Ramesh, D.; Joji, A.; Prakasan, J.J.; Kannan, T. In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. *Eur. J. Pharmacol.* **2020**, *886*, 173448. [[CrossRef](#)]
196. Pandey, A.K.; Verma, S. An in-silico evaluation of dietary components for structural inhibition of SARS-Cov-2 main protease. *J. Biomol. Struct. Dyn.* **2020**, *1–7*. [[CrossRef](#)] [[PubMed](#)]
197. Jo, S.; Kim, S.; Kim, D.Y.; Kim, M.-S.; Shin, D.H. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. *J. Enzym. Inhib. Med. Chem.* **2020**, *35*, 1539–1544. [[CrossRef](#)] [[PubMed](#)]
198. Santangelo, C.; Vari, R.; Scazzocchio, B.; Filesi, C.; Masella, R. Management of reproduction and pregnancy complications in maternal obesity: Which role for dietary polyphenols? *BioFactors* **2013**, *40*, 79–102. [[CrossRef](#)] [[PubMed](#)]
199. Janda, L.; Mihalčin, M.; Štátná, M. Is a healthy microbiome responsible for lower mortality in COVID-19? *Biologia* **2020**, *76*, 819–829. [[CrossRef](#)]
200. He, L.-H.; Ren, L.-F.; Li, J.-F.; Wu, Y.-N.; Li, X.; Zhang, L. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection. *Front. Microbiol.* **2020**, *11*, 1388. [[CrossRef](#)]
201. Conte, L.; Toraldo, D.M. Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. *Ther. Adv. Respir. Dis.* **2020**, *14*. [[CrossRef](#)]
202. Infusino, F.; Marazzato, M.; Mancone, M.; Fedele, F.; Mastroianni, C.M.; Severino, P.; Ceccarelli, G.; Santinelli, L.; Cavarretta, E.; Marullo, A.G.M.; et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. *Nutrients* **2020**, *12*, 1718. [[CrossRef](#)]
203. Shinde, T.; Hansbro, P.M.; Sohal, S.S.; Dingle, P.; Eri, R.; Stanley, R. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives. *Microorganisms* **2020**, *8*, 921. [[CrossRef](#)]

204. Margină, D.; Ungurianu, A.; Purdel, C.; Tsoukalas, D.; Tsoukalas, D.; Thanasoula, M.; Tekos, F.; Mesnage, R.; Kouretas, D.; Tsatsakis, A. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors. *Int. J. Environ. Res. Public Health* **2020**, *17*, 4135. [CrossRef]
205. Fernández-Quintela, A.; Milton-Laskibar, I.; Trepiana, J.; Gómez-Zorita, S.; Kajarabille, N.; Léniz, A.; González, M.; Portillo, M.P. Key Aspects in Nutritional Management of COVID-19 Patients. *J. Clin. Med.* **2020**, *9*, 2589. [CrossRef]
206. Jawhara, S. How to boost the immune defence prior to respiratory virus infections with the special focus on coronavirus infections. *Gut Pathog.* **2020**, *12*, 1–6. [CrossRef] [PubMed]
207. Morais, A.H.A.; Passos, T.S.; Maciel, B.L.L.; Da Silva-Maia, J.K. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection? *Nutrients* **2020**, *12*, 1737. [CrossRef] [PubMed]
208. Peluso, I.; Raguzzini, A. Salivary and Urinary Total Antioxidant Capacity as Biomarkers of Oxidative Stress in Humans. *Pathol. Res. Int.* **2016**, *2016*, 5480267. [CrossRef] [PubMed]
209. Peluso, I.; Palmery, M. Risks of Misinterpretation in the Evaluation of the Effect of Fruit-Based Drinks in Postprandial Studies. *Gastroenterol. Res. Pr.* **2014**, *2014*, 870547. [CrossRef] [PubMed]
210. Peluso, I.; Manafikhi, H.; Reggi, R.; Palmery, M. Effects of red wine on postprandial stress: Potential implication in non-alcoholic fatty liver disease development. *Eur. J. Nutr.* **2015**, *54*, 497–507. [CrossRef] [PubMed]
211. Peluso, I.; Teichner, A.; Manafikhi, H.; Palmery, M. *Camellia sinensis* in asymptomatic hyperuricemia: A meta-analysis of tea or tea extract effects on uric acid levels. *Crit. Rev. Food Sci. Nutr.* **2015**, *57*, 391–398. [CrossRef] [PubMed]
212. Peluso, I.; Serafini, M. Antioxidants from black and green tea: From dietary modulation of oxidative stress to pharmacological mechanisms. *Br. J. Pharmacol.* **2017**, *174*, 1195–1208. [CrossRef]
213. Serafini, M.; Del Rio, D.; Yao, D.N.; Bettuzzi, S.; Peluso, I. *Health Benefits of Tea, in Herbal Medicine: Biomolecular and Clinical Aspects*; Benzie, I.F.F., Wachtel-Galor, S., Eds.; CRC Press: Boca Raton, FL, USA, 2011. Available online: <http://www.ncbi.nlm.nih.gov/pubmed/22593935> (accessed on 29 November 2020).
214. Gabrielli, G.B.; De Sandre, G. Excessive tea consumption can inhibit the efficacy of oral iron treatment in iron-deficiency anemia. *Haematologica* **1995**, *80*, 518–520.
215. Fan, F.S. Iron deficiency anemia due to excessive green tea drinking. *Clin. Case Rep.* **2016**, *4*, 1053–1056. [CrossRef]
216. Lewicka, A.; Szymański, L.; Rusiecka, K.; Lewicka, A.; Kucza, A.; Jakubczyk, A.; Zdanowski, R.; Lewicki, S. Supplementation of Plants with Immunomodulatory Properties during Pregnancy and Lactation-Maternal and Offspring Health Effects. *Nutrients* **2019**, *11*, 1958. [CrossRef]
217. Karekar, S.R.; Pooja, S.G.; Marathe, P.A. A review of clinical studies involving pregnant women registered in the Clinical Trials Registry of India. *Perspect. Clin. Res.* **2020**, *11*, 8–12. [CrossRef]
218. Serafini, M.; Peluso, I. Functional Foods for Health: The Interrelated Antioxidant and Anti-Inflammatory Role of Fruits, Vegetables, Herbs, Spices and Cocoa in Humans. *Curr. Pharm. Des.* **2017**, *22*, 6701–6715. [CrossRef] [PubMed]
219. Bousquet, J.; Anto, J.M.; Czarlewski, W.; Haahtela, T.; Fonseca, S.C.; Iaccarino, G.; Blain, H.; Vidal, A.; Sheikh, A.; Akdis, C.; et al. Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. *Allergy* **2020**. [CrossRef] [PubMed]
220. Santangelo, C.; Zicari, A.; Mandosi, E.; Scazzocchio, B.; Mari, E.; Morano, S.; Masella, R. Could gestational diabetes mellitus be managed through dietary bioactive compounds? Current knowledge and future perspectives. *Br. J. Nutr.* **2016**, *115*, 1129–1144. [CrossRef] [PubMed]
221. Martucci, M.; Ostan, R.; Biondi, F.; Bellavista, E.; Fabbri, C.; Bertarelli, C.; Salvioli, S.; Capri, M.; Franceschi, C.; Santoro, A. Mediterranean diet and inflammaging within the hormesis paradigm. *Nutr. Rev.* **2017**, *75*, 442–455. [CrossRef] [PubMed]
222. Margină, D.; Ungurianu, A.; Purdel, C.; Nițulescu, G.M.; Tsoukalas, D.; Sarandi, E.; Thanasoula, M.; Burykina, T.I.; Tekos, F.; Buha, A.; et al. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease. *Food Chem. Toxicol.* **2020**, *143*, 111558. [CrossRef] [PubMed]
223. Peluso, I.; Yarla, N.S.; Ambra, R.; Pastore, G.; Perry, G. MAPK signalling pathway in cancers: Olive products as cancer preventive and therapeutic agents. *Semin. Cancer Biol.* **2019**, *56*, 185–195. [CrossRef]
224. Rizzo, A.; Sciorsci, R.L.; Magrone, T.; Jirillo, E. Exploitation of some natural products for prevention and/or nutritional treatment of SARS-CoV2 infection. *Endocrine Metab. Immune Disord. Drug Targets* **2020**, *20*, 1–14. [CrossRef]
225. Polito, A.; Peluso, I. Effects of Olive Oil on TNF- α and IL-6 in Humans: Implication in Obesity and Frailty. *Endocr. Metab. Immune Disord. Drug Targets* **2017**, *18*, 63–74. [CrossRef]
226. Peluso, I.; Raguzzini, A.; Serafini, M. Effect of flavonoids on circulating levels of TNF- α and IL-6 in humans: A systematic review and meta-analysis. *Mol. Nutr. Food Res.* **2013**, *57*, 784–801. [CrossRef]
227. Messina, G.; Polito, R.; Monda, V.; Cipolloni, L.; Di Nunno, N.; Di Mizio, G.; Murabito, P.; Carotenuto, M.; Messina, A.; Pisanelli, D.; et al. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work. *Int. J. Mol. Sci.* **2020**, *21*, 3104. [CrossRef] [PubMed]
228. Rogero, M.M.; Leão, M.D.C.; Santana, T.M.; Pimentel, M.V.D.M.; Carlini, G.C.; Da Silveira, T.F.; Gonçalves, R.C.; Castro, I.A. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID. *Free Radic. Biol. Med.* **2020**, *156*, 190–199. [CrossRef] [PubMed]
229. Pham, M.N.; Van Do, V.; Lee, A. Polyphenol-rich foods and risk of gestational diabetes: A systematic review and meta-analysis. *Eur. J. Clin. Nutr.* **2018**, *73*, 647–656. [CrossRef] [PubMed]

230. Panyod, S.; Ho, C.-T.; Sheen, L.-Y. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. *J. Tradit. Complement. Med.* **2020**, *10*, 420–427. [[CrossRef](#)]
231. Adams, K.K.; Baker, W.L.; Sobieraj, D.M. Myth Busters: Dietary Supplements and COVID-19. *Ann. Pharmacother.* **2020**, *54*, 820–826. [[CrossRef](#)]
232. Konakci, G.; Uran, B.N.O.; Erkin, O. In the Turkish News: Coronavirus and “Alternative & complementary” medicine methods. *Complement. Ther. Med.* **2020**, *53*, 102545. [[CrossRef](#)]
233. Wan, C.S.; Teede, H.; Nankervis, A.; Aroni, R. Ethnic Differences in Dietary Management of Gestational Diabetes Mellitus: A Mixed Methods Study Comparing Ethnic Chinese Immigrants and Australian Women. *J. Acad. Nutr. Diet.* **2020**, *120*, 86–102. [[CrossRef](#)]
234. Bailey, R.L.; Pac, S.G.; Fulgoni, V.L.; Reidy, K.C.; Catalano, P.M. Estimation of Total Usual Dietary Intakes of Pregnant Women in the United States. *JAMA Netw. Open* **2019**, *2*, e195967. [[CrossRef](#)]
235. Marra, M.V.; Bailey, R.L. Position of the Academy of Nutrition and Dietetics: Micronutrient Supplementation. *J. Acad. Nutr. Diet.* **2018**, *118*, 2162–2173. [[CrossRef](#)]
236. Izzo, A.A.; Hoon-Kim, S.; Radhakrishnan, R.; Williamson, E.M. A Critical Approach to Evaluating Clinical Efficacy, Adverse Events and Drug Interactions of Herbal Remedies. *Phytother. Res.* **2016**, *30*, 691–700. [[CrossRef](#)]
237. Reza, N.; Deligiannidis, K.M.; Eustis, E.H.; Battle, C.L. Complementary Health Practices for Treating Perinatal Depression. *Obstet. Gynecol. Clin. N. Am.* **2018**, *45*, 441–454. [[CrossRef](#)] [[PubMed](#)]
238. Di Renzo, L.; Gualtieri, P.; Cinelli, G.; Bigioni, G.; Soldati, L.; Attinà, A.; Bianco, F.F.; Caparello, G.; Camodeca, V.; Carrano, E.; et al. Psychological Aspects and Eating Habits during COVID-19 Home Confinement: Results of EHLC-COVID-19 Italian Online Survey. *Nutrients* **2020**, *12*, 2152. [[CrossRef](#)] [[PubMed](#)]
239. Parekh, N.; Deierlein, A.L. Health behaviours during the coronavirus disease 2019 pandemic: Implications for obesity. *Public Health Nutr.* **2020**, *23*, 3121–3125. [[CrossRef](#)] [[PubMed](#)]
240. Assaf-Balut, C.; De La Torre, N.G.; Duran, A.; Fuentes, M.; Bordiú, E.; Del Valle, L.; Familiar, C.; Valerio, J.; Jiménez, I.; Herraiz, M.A.; et al. A Mediterranean Diet with an Enhanced Consumption of Extra Virgin Olive Oil and Pistachios Improves Pregnancy Outcomes in Women Without Gestational Diabetes Mellitus: A Sub-Analysis of the St. Carlos Gestational Diabetes Mellitus Prevention Study. *Ann. Nutr. Metab.* **2019**, *74*, 69–79. [[CrossRef](#)] [[PubMed](#)]
241. Reginato, E.; Pippi, R.; Aiello, C.; Tomaro, E.S.; Ranucci, C.; Eburatta, L.; Bini, V.; Marchesini, G.; De Feo, P.; Fanelli, C.G. Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. *J. Clin. Med.* **2019**, *8*, 851. [[CrossRef](#)]